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INTRODUCTION
CHOLESTEROL
Cholesterol is a fat (lipid) which is produced by the liver and is crucial for normal
body functioning. Cholesterol exists in the outer layer of every cell in our body and
has many functions. It is a waxy steroid and is transported in the blood plasma of all
animals. It is the main sterol synthesized by animals - small amounts are also
synthesized in plants and fungi.
The word "cholesterol" comes from the Greek word chole, meaning "bile", and the
Greek word stereos, meaning "solid, stiff".
Functions of cholesterol
 It builds and maintains cell membranes (outer layer), it prevents
crystallization of hydrocarbons in the membrane
 It is essential for determining which molecules can pass into the cell and
which cannot (cell membrane permeability)
 It is involved in the production of sex hormones (androgens and estrogens)
 It is essential for the production of hormones released by the adrenal glands
(cortisol, corticosterone, aldosterone, and others)
 It aids in the production of bile
 It converts sunshine to vitamin D
 It is important for the metabolism of fat soluble vitamins, including vitamins
A, D, E, and K
 It insulates nerve fibers
There are three main types of lipoproteins
Cholesterol is carried in the blood by molecules called lipoproteins. A
lipoprotein is any complex or compound containing both lipid (fat) and protein.
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The three main types are:
LDL (low density lipoprotein)
People often refer to it as bad cholesterol. LDL carries cholesterol from the liver to
cells. If too much is carried, too much for the cells to use, there can be a harmful
buildup of LDL. This lipoprotein can increase the risk of arterial disease if levels
rise too high. Most human blood contains approximately 70% LDL - this may vary,
depending on the person.
HDL (high density lipoprotein)
People often refer to it as good cholesterol. Experts say HDL prevents arterial
disease. HDL does the opposite of LDL - HDL takes the cholesterol away from the
cells and back to the liver. In the liver it is either broken down or expelled from the
body as waste.
Triglycerides
These are the chemical forms in which most fat exists in the body, as well as in
food. They are present in blood plasma. Triglycerides, in association with
cholesterol, form the plasma lipids (blood fat). Triglycerides in plasma originate
either from fats in our food, or are made in the body from other energy sources, such
as carbohydrates. Calories we consume but are not used immediately by our tissues
are converted into triglycerides and stored in fat cells. When your body needs energy
and there is no food as an energy source, triglycerides will be released from fat cells
and used as energy - hormones control this process.
Normal cholesterol levels
The amount of cholesterol in human blood can vary from 3.6 mmol/liter to 7.8
mmol/liter. The National Health Service (NHS), UK, says that any reading over 6
mmol/liter is high, and will significantly raise the risk of arterial disease. The UK
Department of Health recommends a target cholesterol level of under 5 mmo/liter.
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Unfortunately, two-thirds of all UK adults have a total cholesterol level of at least
five (average men 5.5, average women 5.6).
Below is a list of cholesterol levels and how most doctors would categorize them in
mg/dl (milligrams/deciliter) and 5mmol/liter (millimoles/liter).
 Desirable - Less than 200 mg/dL
 Bordeline high - 200 to 239 mg/dL
 High - 240 mg/dL and above
 Optimum level: less than 5mmol/liter
 Mildly high cholesterol level: between 5 to 6.4mmol/liter
 Moderately high cholesterol level: between 6.5 to 7.8mmol/liter
 Very high cholesterol level: above 7.8mmol/liter
Dangers of high cholesterol levels
Atherosclerosis - narrowing of the arteries.
Higher coronary heart disease risk - an abnormality of the arteries that supply
blood and oxygen to the heart.
Heart attack - occurs when the supply of blood and oxygen to an area of heart
muscle is blocked, usually by a clot in a coronary artery. This causes your heart
muscle to die.
Angina - chest pain or discomfort that occurs when your heart muscle does not get
enough blood.
Other cardiovascular conditions - diseases of the heart and blood vessels.
Stroke and mini-stroke - occurs when a blood clot blocks an artery or vein,
interrupting the flow to an area of the brain. Can also occur when a blood vessel
breaks, Brain cells begin to die. If both blood cholesterol and triglyceride levels are
high, the risk of developing coronary heart disease rises significantly.
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Symptoms of high cholesterol (hypercholesterolaemia):
Symptoms of high cholesterol do not exist alone in a way a patient or doctor can
identify by touch or sight. Symptoms of high cholesterol are revealed if you have the
symptoms of atherosclerosis, a common consequence of having high cholesterol
levels. These can include:
 Narrowed coronary arteries in the heart (angina)
 Leg pain when exercising - this is because the arteries that supply the legs
have narrowed.
 Blood clots and ruptured blood vessels - these can cause a stroke or TIA
(mini-stroke).
 Ruptured plaques - this can lead to coronary thrombosis (a clot forming in
one of the arteries that delivers blood to the heart). If this causes significant
damage to heart muscle it could cause heart failure.
 Xanthomas - thick yellow patches on the skin, especially around the eyes.
They are, in fact, deposits of cholesterol. This is commonly seen among
people who have inherited high cholesterol susceptibility (familial or
inherited hypercholesterolaemia).
CAUSES FOR HIGH CHOLESTEROL
Lifestyle causes:
Nutrition - although some foods contain cholesterol, such as eggs, kidneys, eggs
and some seafoods, dietary cholesterol does not have much of an impact in human
blood cholesterol levels. However, saturated fats do! Foods high in saturated fats
include red meat, some pies, sausages, hard cheese, lard, pastry, cakes, most
biscuits, and cream (there are many more).
Sedentary lifestyle - people who do not exercise and spend most of their time
sitting/lying down have significantly higher levels of LDL (bad cholesterol) and
lower levels of HDL (good cholesterol).
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Bodyweight - people who are overweight/obese are much more likely to have
higher LDL levels and lower HDL levels, compared to people who are of normal
weight.
Smoking - this can have quite a considerable effect on LDL levels.
Alcohol - people who consume too much alcohol regularly, generally have much
higher levels of LDL and much lower levels of HDL, compared to people who
abstain or those who drink in moderation.
TREATMENTS FOR HIGH CHOLESTEROL
Lifestyle
Most people, especially those whose only risk factor has been lifestyle, can
generally get their cholesterol and triglyceride levels back to normal by:
 Doing plenty of exercise (check with your doctor)
 Eating plenty of fruits, vegetables, whole grains, oats, good
quality fats
 Avoiding foods with saturated fats
 Getting plenty of sleep (8 hours each night)
 Bringing your bodyweight back to normal
 Avoiding alcohol
 Stopping smoking
Cholesterol-controlling medications
If your cholesterol levels are still high after doing everything mentioned above, your
doctor may prescribe a cholesterol-lowering drug. They may include the following:
 Statins (HMG-CoA reductase inhibitors) - these block an enzyme
in your liver that produces cholesterol. The aim here is to reduce your
cholesterol levels to under 4 mmol/liter and under 2 mmol/liter for
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your LDL. Statins are useful for the treatment and prevention of
atherosclerosis. Side effects can include constipation, headaches,
abdominal pain, and diarrhea. Atorvastatin, fluvastatin, lovastatin,
pravastatin, rosuvastatin and simvastatin are examples of statins.
 Aspirin - this should not be given to patients under 16 years of age.
Drugs to lower triglyceride levels - these are fibric acid derivatives
and include gemfibrozil, fenofibrate and clofibrate.
 Niacin - this is a B vitamin that exists in various foods. You can only
get very high doses with a doctor's prescription. Niacin brings down
both LDL and HDL levels. Side effects might include itching,
headaches, hot flashes (UK: flushes), and tingling (mostly very mild
if they do occur).
 Anti-hypertensive drugs - if you have high blood pressure your
doctor may prescribe Angiotensin-converting enzyme (ACE)
inhibitors, Angiotensin II receptor blockers (ARBs), Diuretics, Beta-
blockers, Calcium channel blockers.
 In some cases cholesterol absorption inhibitors (ezetimibe) and bile-
acid sequestrants may be prescribed. They have more side effects and
require considerable patient education to achieve compliance (to
make sure drugs are taken according to instruction).
Total Cholesterol Levels
The sum of different cholesterol types in your blood is referred to as total
cholesterol. This measurement, while good, can be occasionally misleading.
Generally, more specific measurements are needed for better understanding the issue
& choosing the right treatment, more so for those with history of diabetes or
coronary artery disease. As a general rule, higher levels of cholesterol mean higher
risk of coronary heart disease. Drop of cholesterol by 1 point achieves
approximately 2% risk drop of heart disease. (Christian Nordquist, 2009)
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Cholesterol Levels by The American Heart Association
Less than 200 mg/dL - Optimal
200 – 239 mg/dL- Borderline high
240 mg/dL or higher - High Cholesterol – over 200% the risk of coronary heart
disease in comparison to someone with optimal levels
HDL Cholesterol Levels
High-density lipoproteins (HDLs), also known as good cholesterol, act like waste
removal carriers. They move the cholesterol from your blood and artery walls to
your liver for removal from your body. About 1/3 to 1/4 of blood cholesterol is
carried by HDL. For this reason, obviously, higher HDL cholesterol levels are
desirable.
Less than 40 mg/dL (men), 50 mg/dL (women)--Such HDL cholesterol levels are a
major risk for heart.
60 mg/dL or above- Optimal – HDL cholesterol of 60 mg/dL & above is protective
High triglyceride levels, physical inactivity, being overweight, obese, smoking, high
carbohydrate intakes, type two diabetes, some medications as well as genetic factors
can contribute to low HDL cholesterol levels.
LDL Cholesterol Levels
Low-density lipoproteins (LDLs), also known as bad cholesterol, keep blood
cholesterol circulating in your bloodstream, leaving plaque on artery walls along the
way. As this process develops over time, up goes atherosclerosis risk. Obviously,
lower LDL cholesterol levels are desirable.
Less than 100 mg/dL - Optimal
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100 – 129 mg/dL - Near optimal
130 – 159 mg/dL - Borderline high
160 – 189 mg/dL - High
190 mg/dL or above - Very high
Triglycerides Levels
High blood triglycerides generally mean lower HDL cholesterol, higher risk of heart
attack & stroke. Additionally, underlying diseases or genetic disorders such as
diabetes, high blood pressure, smoking, obesity & insulin resistance generally keep
company to high triglycerides levels. The main therapy is a lifestyle change.
Triglycerides Levels by The American Heart Association
Less than 150 mg/dL - Normal
150 – 199 mg/dL - Borderline high
200 – 499 mg/dL - High
500 mg/dL or above - Very high
Antihyperlipidemic agents
Antihyperlipidemic agents promote reduction of lipid levels in the blood. Some
antihyperlipidemic agents aim to lower the levels of low-density lipoprotein (LDL)
cholesterol, some reduce triglyceride levels, and some help raise the high-density
lipoprotein (HDL) cholesterol. By reducing the LDL cholesterol, they can prevent
both the primary and secondary symptoms of coronary heart disease.
Cholesterol is found in each and every cell of our body. Cholesterol is a water
repelling compound and so it does not get dissolved in the bloodstream. It is a waxy
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steroid metabolite. It is required for the proper functioning of the body. It is required
for the production of vitamin D, hormones and bile juices. Low-Density Lipoprotein
(LDL) or bad cholesterol and High-Density Lipoprotein (HDL) or good cholesterol
are the two types of cholesterol. Simple blood test helps measure cholesterol levels
in the body. The ideal LDL:HDL ratio and the ideal cholesterol levels are same for
all ages. As you are looking for cholesterol range by age, here is the required
information regarding normal cholesterol range.
LDL Cholesterol Goals and Risk Factors
Maintaining low levels of LDL and high levels of HDL is essential if you want to
lead a healthy and active life. High levels of LDL increase the risk of cardiovascular
diseases, cancer and stroke. The ideal cholesterol range by age may vary slightly as
your LDL cholesterol goal depends on how many other risk factors (diabetes,
coronary heart diseases, obesity, etc.) you have. The risk of high cholesterol is
ascertained by taking into account your age, sex, family history, weight, blood
pressure and lifestyle habits. Along with aging, the influence of risk factors
increases. Therefore healthy cholesterol levels by age may differ slightly. But there
cannot be a fixed cholesterol chart by age or fixed numbers indicating cholesterol
range by age. Children with diabetes or heart problems or obese children also need
to watch for LDL, HDL levels.
Cholesterol Ratio
There cannot be cholesterol ratio by age. The desired cholesterol ratio may change
slightly according to the risk factors, as explained above. Here follows
Total Cholesterol/HDL: The ideal cholesterol ratio of total cholesterol and HDL is
3.5:1.
HDL/LDL: 0.4:1 is the ideal cholesterol ratio for HDL/LDL.
LDL/HDL: The ideal cholesterol ratio of LDL/HDL is 2.5:1 (kevin Belargo, 2008)
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LIPIDS
Lipids are a broad group of naturally occurring molecules which includes fats,
waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E and K),
monoglycerides, diglycerides, phospholipids, and others. The main biological
functions of lipids include energy storage, as structural components of cell
membranes, and as important signaling molecules.(Fahy E et al., 2009)
Lipids may be broadly defined as hydrophobic or amphiphilic small molecules; the
amphiphilic nature of some lipids allows them to form structures such as vesicles,
liposomes, or membranes in an aqueous environment. Biological lipids originate
entirely or in part from two distinct types of biochemical subunits or "building
blocks": ketoacyl and isoprene groups. Using this approach, lipids may be divided
into eight categories: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids,
saccharolipids and polyketides (derived from condensation of ketoacyl subunits);
and sterol lipids and prenol lipids (derived from condensation of isoprene subunits).
Although the term lipid is sometimes used as a synonym for fats, fats are a subgroup
of lipids called triglycerides. Lipids also encompass molecules such as fatty acids
and their derivatives (including tri-, di-, and monoglycerides and phospholipids), as
well as other sterol-containing metabolites such as cholesterol. (Michelle et al.,
1993) (Subramaniam et al., 1993) Although humans and other mammals use
various biosynthetic pathways to both break down and synthesize lipids, some
essential lipids cannot be made this way and must be obtained from the diet.
CATEGORIES OF LIPIDS
 Fatty acyls
 Glycerolipids
 Glycerophospholipids
 Sphingolipids
 Sterol lipids
 Prenol lipids
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 Saccharolipids
 Polyketides
BIOLOGICAL FUNCTIONS
 Membranes
 Energy storage
 Signaling
 Metabolism
 Biosynthesis
 Degradation
 Nutrition and health
 Lipid Metabolism
A few studies have suggested that total dietary fat intake is linked to an increased
risk of obesity and diabetes. However, a number of very large studies, including the
Women's Health Initiative Dietary Modification Trial, an eight year study of 49,000
women, the Nurses' Health Study and the Health Professionals Follow-up Study,
revealed no such links. None of these studies suggested any connection between
percentage of calories from fat and risk of cancer, heart disease or weight gain. The
Nutrition Source, a website maintained by the Department of Nutrition at the
Harvard School of Public Health, summarizes the current evidence on the impact of
dietary fat: "Detailed research—much of it done at Harvard—shows that the total
amount of fat in the diet isn't really linked with weight or disease.
Table 1. Apolipoproteins associated with lipoproteins
Apolipoproteins Lipoprotein association Comments
apoA1 Chylomicron, HDL Major protein of HDL, activates
LCAT
apoA2 Chylomicron, HDL Enhances hepatic lipase activity
apoA4 Chylomicron, HDL Co-factor for LPL activation,
may have a role in chylomicron
and VLDL secretion and
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catabolism, activates LCAT
apoA5 HDL Activates LPL
apoB48 Chylomicron Exclusively found in
chylomicrons, alternative splice
product of the apoB100 gene
thereby lacking the LDL
receptor-binding domain
apoB100 VLDL, IDL, LDL Ligand for the LDL receptor
apoC1 Chylomicron, VLDL, IDL, HDL Appears to modulate the
interaction of apoE with β-VLDL
and inhibit binding of β-VLDL
to LRP
apoC2 Chylomicron, VLDL, IDL, HDL Activates LPL
apoC3 Chylomicron, VLDL, IDL, HDL Inhibits LPL
apoE Chylomicron, VLDL, IDL, HDL Ligand for LDL receptor and
LRP
Based on their size, lipid and apolipoprotein composition, lipoproteins can be
categorized into five classes: chylomicrons, very low density lipoprotein (VLDL),
intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and the high
density lipoprotein (HDL). However, heterogeneity exists within each class because
of the constant remodelling of their composition, shape, size, and surface charge,
and exchange of protein and lipid constituents.
The liver plays a central role in lipid metabolism. Lipoprotein trafficking
from and to the liver proceeds along two pathways: the endogenous and the
exogenous pathway cholesterol transport from peripheral tissues to the liver is often
considered as the third pathway.
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Figure No.1 Exogenous and Endogenous pathway
The exogenous pathway involves the uptake of dietary lipids by the intestine
followed by their transport through the body via lipoproteins. After the lipid intake,
the triglycerides and the cholesteryl esters will be hydrolyzed in the intestine and
subsequently assembled into chylomicrons. These large triglyceride-rich
chylomicrons containing apoA1, apoA2, apoA4, and apoB48 are secreted into the
lymph in order to transport entrapped lipids to the circulation. In the bloodstream,
the chylomicrons exchange apoA1 and associated apoA4 for apoC1, apoC2, apoC3,
and apoE with HDL which subsequently results in the formation of the more
cholesterol-rich chylomicron remnants due to loss of triglycerides to peripheral
tissue. ApoC2 is an activator of the lipolytic enzyme lipoprotein lipase (LPL), which
is associated with the capillary endothelium of skeletal muscle, cardiac muscle, and
adipose tissue. ApoC2 aided interaction of chylomicrons with LPL allows the
lipolysis of its core triglycerides leading to the formation of free fatty acids which
are taken up by surrounding tissue for further use. Lipolysis gradually becomes less
efficient due to depletion of the LPL co-activator apoC2. Eventually the
chylomicron remnants, enriched in cholesteryl esters, apoB48, and apoE, are
eliminated from the circulation by the liver mainly via the uptake by the LDL-
Chapter 1                                                                                                    Introduction
Dept. of Pharmacology 14 JKK Nattraja College of Pharmacy
receptor which specifically recognizes apoE and apoB100, and by the LDL-receptor
related protein (LRP).
The liver produces the triglyceride-rich lipoprotein, VLDL, which is
introduced into the endogenous pathway. Some of the VLDL contained triglycerides
will be derived from internalized chylomicron remnants, but the bulk of the VLDL
triglycerides are synthesized de novo in the liver from fatty acids produced from
dietary carbohydrate derived Acetyl-CoA. The formation of VLDL starts with the
transfer of lipids towards the major structural protein of VLDL, apolipoprotein B100
(apoB100). This transfer is catalyzed by the microsomal triglyceride transfer protein
(MTP), making this enzyme a key factor in the assembly of VLDL. Subsequently
before secretion into the blood circulation, the pre-VLDL particle acquires apoC1,
apoC2, apoC3, and ApoE. ApoE plays a critical role when it comes to secretion of
VLDL and clearance of VLDL remnants. Similar to chylomicrons, VLDL transports
triglycerides to skeletal muscle, cardiac muscle, and adipose tissue and also serves
as substrate for LPL lipolysis in the circulation. As a result, VLDL particles
gradually reduce in size due to hydrolysis of the triglycerides leading to the
formation of the more cholesterol-rich IDL. Small sized VLDL and IDL are also
referred to as VLDL remnants. These remnants are partially cleared by the liver
through an apoE-mediated process while the remainder can be converted to LDL.
The conversion to LDL is accompanied not only by a further loss in triglycerides but
also by the depletion of apoE and the apoC’s. With apoB100 as sole apolipoprotein
constituent of LDL, LDL can be cleared by the liver or taken up by peripheral tissue
via the LDL receptor. High levels of LDL and/or VLDL remnants are considered as
important risk factors for atherosclerosis, and are therefore also termed atherogenic
lipoproteins.
Reverse cholesterol transport
While the first two pathways focuses mainly on the transport of
triglycerides from intestine and liver to peripheral tissue via apoB-containing
lipoproteins followed by the clearance of cholesterol-rich lipoprotein remnants, the
third pathway involves the net transport of (excess) cholesterol from peripheral
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tissue back to the liver where it can be removed from the body via the bile by
conversion to bile acids or as biliary cholesterol. The reverse transport of cholesterol
is mediated by the lipoprotein HDL, of which the metabolism is complex and only
partially understood. HDL is a heterogeneous class of lipoprotein particles existing
of different sub fractions that differ in apolipoprotein and lipid composition, size,
density, and even physiologic function. However, apoA1 plays a key role in the
biogenesis and function of all HDL subclasses. Generation of HDL starts with the
intestinal and hepatic synthesis and secretion of lipid-poor apoA1. This apoA1
‘particle’ acquires phospholipids and unesterified cholesterol from cell membranes
and plasma lipoprotein to convert into a discoidal preβ-HDL particle. Both nascent
pre-HDL particles are potent cholesterol acceptors and take up free cholesterol from
peripheral cells and, importantly from a cardiovascular point of view, macrophages.
This cholesterol efflux is mediated by the integral membrane protein ATP-binding
cassette transporter A-1 (ABCA1), which actively transports cellular cholesterol
(and phospholipids) to the nascent HDL. The importance of ABCA1 in reverse
cholesterol was established in patients with Tangier disease, who are characterized
by HDL deficiency. This disease is caused by a dysfunctional ABCA1 and results in
massive accumulation of cholesterol in tissue macrophages and prevalent
atherosclerosis. Cholesterol taken up by the nascent HDL particles will be esterified
by the enzyme lecithin: cholesterol acyltransferase (LCAT), transforming nascent
preβ-HDL into larger spherical HDL-particles. Subsequently, the latter HDL
particles are subjected to remodelling after interaction with other plasma
lipoproteins or tissues. For instance, the cholesteryl ester transfer protein (CETP)
catalyzes the exchange of cholesteryl esters for triglycerides with apoB-containing
lipoproteins. The uptake of HDL cholesterol by the liver is mainly mediated by the
scavenger receptor class B1 (SR-B1). Once in the liver, cholesterol can be re-used
for lipoprotein assembly, used as substrate for bile acid synthesis, or secreted
directly as free cholesterol into the bile.
Although during the last years classifications of the different stages of HDL
have become as intricate as the particle itself due to the various compositions, sizes,
functions, etc., it is becoming increasingly clear that HDL plays a significant role in
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cholesterol homeostasis. Particularly the role of HDL in reverse cholesterol transport
and the athero-protective characteristics of this particle are widely accepted
Genetic factors in dyslipidemia
The expression of lipid-related genes under normal conditions is tightly
coordinated in order to maintain lipid homeostasis. Unfortunately, in western
societies and in emerging economies a large part of the population suffer from a
perturbed lipid homeostasis resulting in unbalanced plasma levels of the different
lipoproteins and an increased incidence of coronary events and cardiovascular
deaths. Although factors such as high cholesterol consumption and increasing age
are important, undesirable lipoprotein profiles are also determined by genetic factors
such as dysfunctional genes.
Familial hypercholesterolemia (FH), one of the most common causes of
hypercholesterolemia, was the first genetic disease of lipid metabolism to be
characterized. Patients suffer from elevated plasma levels of LDL-cholesterol caused
by mutations in the LDL-receptor gene. To date, well over 500 mutations of the
LDL-receptor have been identified. The severity of the hypercholesterolemia
depends on the nature of the molecular defect and whether the mutation is homo- or
heterozygous. Patients with homozygous FH develop significant atherosclerotic
heart disease at a relative early age. The clinical prognosis of patients with
heterozygous FH is related not only to the magnitude of the elevation in plasma
LDL-cholesterol levels, but also to the presence of other cardiovascular risk factors.
A disease that shows similarity with FH in that it also results in a reduced
uptake of LDL by the LDL-receptor is familial defective apoB100 (FDB). This
disease is caused by several mutations in apoB100 at the postulated binding site to
the LDL-receptor. However, the phenotype of patients homozygous for FDB
generally is less severe than that of FH patients. The latter is the result of a reduced
formation rate of LDL particles in the plasma, since FDB patients are still able to
clear the LDL precursor particles (VLDL, IDL, and their remnants) via apoE
mediated uptake Polymorphisms in lipid related genes, such as apoE, also
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predispose to cardiovascular diseases. Three major apoE isoforms, E2, E3, and E4,
are encoded by three common alleles at the apoE gene locus: E2, E3, and E4. The
apoE2 isoform is associated with lower and that of apoE4 with elevated total
plasma- and LDL-cholesterol levels than the more common apoE3 isoform. These
three isoforms differ in their affinity for the LDL receptor which can influence the
serum profile and levels of apoE containing lipoproteins. For example, the majority
of patients with type III hyperlipidemia, which is characterized by elevated levels of
cholesteryl ester enriched remnant particles; appear to be homozygous for apoE2.
The apoE4 allele, which is receiving great attention due to its linkage to Alzheimer's
disease, is associated with an increased prevalence for cardiovascular disease
especially in populations consuming diets rich in saturated fat and cholesterol.
Many other, mostly rare, single lipid-related gene mutations such as the
ABCA1 mutations found in patients with Tangier disease discussed earlier have
been described. However, these and the aforementioned examples are of monogenic
nature and, with the exception of FH, show a low frequency. Dyslipidemia being a
multifactorial process, the major portion of this predisposition is polygenic,
reflecting cumulative effects of multiple genetic sequence variants. These hereditary
factors are difficult to identify since possible dyslipidemia phenotypes are the result
of complex interactions between genetic and environmental factors.
Central role of the liver in lipid metabolism
As indicated above, maintenance of lipid homeostasis is the sum of
numerous complex physiological processes both at an organ, and at a cellular level.
The organ that plays a key role in the synthesis and catabolism of lipids is the liver.
It expresses enzymes that are responsible for synthesis (e.g. fatty acid synthetase and
HMG-CoA reductase) of triglycerides and cholesterol (esters). Excess of cholesterol
can be metabolized in the liver via enzymes such as cholesterol-7-α-hydroxylase and
sterol 27-hydroxylase (cyp7A1 and cyp27, respectively), and removed from the
body via bile acid synthesis. Further, it is involved in assembly and secretion of the
main lipoproteins, i.e. VLDL and HDL, and the elimination of serum lipoproteins
via lipoprotein receptors. Most, if not all, apolipoproteins involved in the
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metabolism of lipoproteins 16 General Introduction is expressed in the liver. In
order to prevent high lipid levels, which correlate with increased risk of
cardiovascular disorders, it is essential that the expression of lipid-related genes in
the liver is well orchestrated. Several aspects and processes will be highlighted
below
Figure No 2.
Intestine Liver Peripheral Tissue
Lipoprotien synthesis:
Via the formation of triglycerides-rich lipoproteins in the liver, lipids are distributed
throughout the body. Hepatic assembly and secretion of apoB-containing VLDL
requires a temporary pool of lipids to form the monolayer surface (mainly
phosphatidyl choline and cholesterol) and the neutral lipid core, the production of
the structural protein apoB, and the rate limiting enzyme MTP. The lipid pool used
for VLDL synthesis is fed by two sources: uptake of dietary lipids and de novo
synthesis. Important rate limiting enzymes for the synthesis of fatty acids are acetyl-
CoA carboxylase and fatty acid synthase, while the enzymes HMG-CoA synthase
and HMG-CoA reductase are major check points in cholesterol synthesis. The
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availability of lipids and rate of lipid biosynthesis, lipogenesis, influence the rate of
VLDL assembly and secretion.
The structural protein of VLDL is apoB. ApoB exists in two forms: the full length
apoB100 and a truncated protein that contains only 48% of the full length version,
apoB48. ApoB48 is the result of post-transcriptional modification of apoB100
mRNA by a cytidine deaminase (apobec1) containing enzyme complex. In humans,
apobec1 is solely active in the intestine, and unlike rodents, no hepatic apobec1
expression can be found. Hence, VLDL particles synthesized in human liver only
contain apoB100. Although apoB100 is the major apolipoprotein of VLDL, a
significant portion of newly synthesized apoB is degraded intracellular via several
possible proteosomal and non-proteosomal processes prior to secretion. Studies
showing that an increased apoB100 secretion is not accompanied by a detectable
change in apoB mRNA, support the notion that apoB100 production is regulated at a
post-transcriptional level by means of degradation. The underlying mechanisms of
degradation and its regulatory control have not been completely elaborated, but it
has become clear that premature degradation can be prevented by translocation
across the endoplasmic reticulum (ER) and subsequent lipidation of the nascent
apoB100. The protein crucial for these processes is MTP, which resides in the lumen
of the ER as a heterodimer with the ubiquitous ER-enzyme, protein-disulfide
isomerase. The latter seems to be required by MTP for its solubility, ER retention,
and for lipid-transfer-activity of MTP. In the ER, MTP binds to newly synthesized
lipid-poor apoB and facilitates the transfer of triglycerides, cholesterol esters, and
phospholipids. Recent studies indicate that during the lipidation process the affinity
of MTP for apoB decreases, allowing at a certain point the dissociation of MTP
from ApoB, and the formation of a secretion-competent primordial VLDL. Based on
findings with conditional liver-specific MTP gene knockout mice, specific MTP
inhibitors, and hepatic MTP over expression in mice, MTP is considered to be the
rate-limiting enzyme in the VLDL assembly/secretion pathway.
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Hepatic uptake and removal of cholesterol
As described above, cholesterol-rich remnants and HDL are cleared from the plasma
via hepatic receptors. The main receptors responsible for the uptake of chylomicron-
and VLDL-remnants, and LDL are the LDL receptor and LRP. Given the
importance of the reverse cholesterol pathway in lipid homeostasis, the
identification of the HDL-receptor, scavenger receptor class B type 1 (SR-B1) was a
breakthrough. SR-B1 is a cell-surface transmembrane protein which functions as a
high affinity receptor for HDL, but also can bind a wide variety of other ligands
including LDL and VLDL. Not only does SR-B1 bind HDL, but it also mediates
selective lipoprotein cholesterol uptake. This selective uptake involving cholesterol
delivery from plasma HDL to the liver without particle degradation does not require
co-factors. Upon cholesterol uptake, the cholesterol can be stored in the liver after
conversion to cholesteryl esters by acyl-CoA: cholesterol acyltransferase (ACAT).
The intracellular cholesterol pool can be re-used for assembly of VLDL or
eliminated from the liver via bile directly or via bile acid synthesis.
Direct secretion of cholesterol into the bile proceeds through two ATP-binding
cassette (ABC) transporters, ABCG5 and ABCG8. These ATP dependent sterol
transporters function as obligate heterodimers to promote sterol excretion into the
bile. Conversion of cholesterol into bile acid involves a cascade of reactions and
almost 20 different enzymes have been identified. Basically, at present two
pathways exist for bile acid synthesis. The classical neutral pathway, which is the
main route, involves the rate-limiting enzyme cholesterol 7α-hydroxylase (cyp7A1),
and leads to the production of mainly cholic acid. The alternative pathway or acidic
pathway is initiated by the enzyme sterol 27-hydroxylase (cyp27) which
preferentially produces chenodeoxycholic acid. Both bile acids can be transported
into the bile after which the bile acids are secreted into the intestine to leave the
body or to be re-absorbed. (Douglas Adams., 1971)
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CHOLESTEROL
Cholesterol is a chemical compound that is naturally produced by the body and is
structurally a combination of lipid (fat) and steroid. Cholesterol is a building block
for cell membranes and for hormones like estrogen and testosterone. About 80% of
the body's cholesterol is produced by the liver, while the rest comes from our diet.
The main sources of dietary cholesterol are meat, poultry, fish, and dairy products.
Organ meats, such as liver, are especially high in cholesterol content, while foods of
plant origin contain no cholesterol. After a meal, dietary cholesterol is absorbed
from the intestine and stored in the liver. The liver is able to regulate cholesterol
levels in the blood stream and can secrete cholesterol if it is needed by the body.
LDL AND HDL CHOLESTEROL
LDL cholesterol is called "bad" cholesterol, because elevated levels of LDL
cholesterol are associated with an increased risk of coronary heart disease, stroke,
and peripheral artery disease. LDL lipoprotein deposits cholesterol along the inside
of artery walls, causing the formation of a hard, thick substance called cholesterol
plaque. Over time, cholesterol plaque causes thickening of the artery walls and
narrowing of the arteries, a process called atherosclerosis, which decreases blood
flow through the narrowed area.
HDL cholesterol is called the "good cholesterol" because HDL cholesterol particles
prevent atherosclerosis by extracting cholesterol from the artery walls and disposing
of them through the liver. Thus, high levels of LDL cholesterol and low levels of
HDL cholesterol (high LDL/HDL ratios) are risk factors for atherosclerosis, while
low levels of LDL cholesterol and high levels of HDL cholesterol (low LDL/HDL
ratios) are desirable and protect against heart disease and stroke.
Total cholesterol is the sum of LDL (low density) cholesterol, HDL (high density)
cholesterol, VLDL (very low density) cholesterol, and IDL (intermediate density)
cholesterol.
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HDL (Good) Cholesterol
HDL cholesterol particles prevent atherosclerosis by extracting cholesterol from the
artery walls and disposing of them through the liver. Thus, high levels of LDL
cholesterol and low levels of HDL cholesterol (high LDL/HDL ratios) are risk
factors for atherosclerosis, while low levels of LDL cholesterol and high level of
HDL cholesterol (low LDL/HDL ratios) are desirable making them known as good
cholesterol. Both heredity and diet have a significant influence on a person's LDL,
HDL and total cholesterol levels.
Lowering your LDL cholesterol is easier to do than raising your HDL cholesterol.
However, there is great benefit in bringing your HDL numbers up and even greater
benefit by doing both - lowering LDL/raising HDL.
For a long time, focus was primarily on LDL and the need to bring numbers down.
However, researchers and physicians have now identified that bringing the HDL
level up is just as beneficial and a natural way of fighting off bad cholesterol.
Although more difficult to accomplish, there are definite steps you can take to help
raise your HDL:
 Weight Loss
 Exercise
 B3 (Niacin)
Some studies have shown that when antioxidants are coupled with cholesterol-
reducing medications such as Statin-type drugs along with Niacin, there was some
level of benefit. Further research suggests that in women with high plasma levels of
HDL, the risk of heart attack becomes reduced.
The higher your HDL levels the better. Today, the average for women is between 50
and 55 mg/dL and for men 40 to 45 mg/dL. Again, getting this level over 60 is a
very effective start toward improving overall cholesterol ratios.
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LDL (Bad) Cholesterol
LDL cholesterol is called "bad" cholesterol, because elevated levels of LDL
cholesterol are associated with an increased risk of coronary heart disease (CHD).
Lipoprotein deposits cholesterol on the artery walls forming a hard layer called the
plaque which obstructs the flow of blow of blood to the heart. This cholesterol
plaque causes thickening of the artery walls and narrowing of the arteries, a process
called atherosclerosis.
The liver not only manufactures and secretes LDL cholesterol into the blood; it also
Apart from removing LDL cholesterol from the blood the liver also produces and
secretes LDL cholesterol into the blood. A high number of active LDL receptors on
the liver surfaces is associated with the rapid removal of LDL cholesterol from the
blood and low blood LDL cholesterol levels. High LDL cholesterol blood levels are
often associated with the deficiency of these LDL receptors.
Lowering LDL cholesterol is the primary focus in preventing atherosclerosis and
heart attacks. The benefits of lowering LDL cholesterol include:
 Reducing or stopping the formation of new cholesterol plaques on the artery
walls;
 Removing or reduction of existing cholesterol plaques on the artery walls;
 Opening up of the narrowed arteries;
 Avoid rupturing the cholesterol plaques, which facilitate formation of blood
clots.
 Decreasing the risk of heart attacks; and
 Decreasing the risk of strokes.
Lowering LDL (Bad) Cholesterol
Various studies have shown that chances of having a heart attack are actually
decreased by as much as 25% for every 10% drop in cholesterol level. Lowering
LDL cholesterol is a key factor in bringing total cholesterol down to a safe level.
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Lowering LDL: Advantages
 Chances of heart attack and/or stroke are decreased
 Formation of new cholesterol plaques is reduced
 Existing plaques are removed
 Rupture of existing plaques is prevented
A particular study confirmed risks of heart attack/stoke and even deaths are reduced
considerably by lowering LDL. In this study, more than 4,000 people with
confirmed heart disease were given either a cholesterol-lowering drug called statin
or a placebo. Results showed that for the people taking the Statin, the total
cholesterol levels were reduced 25%, LDL was lowered 35%, and death occurring
from heart disease was reduced by a staggering 42%.
Daily calorie intake of fat should be cut down to less than 30%. Consuming too
many calories from all kinds of food, whether it is carbohydrates, proteins, or fats,
the body will absorb the food and turn it into triglycerides which are then circulated
in the bloodstream to be later stored as fat.
Lowering LDL levels has a great impact on their health of people suffering from
heart disease. The more the LDL level the higher is the risk of a heart attack. If you
have high LDL levels, better to consult a physician and follow his advice to bring
them down.
Triglycerides (VLDL Cholesterol)
Triglycerides are a particular form of fat that is transported through your blood to
the tissue. The majority of your body's fat tissue is made up of triglycerides.
However, high level of triglyceride in the blood can be a risk for heart disease.
Triglycerides is usually measured when you have your LDL cholesterol is checked
by your physician. The optimal number for your triglycerides would be anything
150 or less.
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Serum triglycerides come from two sources. The first source is the foods that you
eat. If you consume a meal containing a lot of fat, your intestine will package some
of those fats and transport them to your liver. The second source is your actual liver.
Once the fats are received by the liver, it then takes fatty acids released by your fat
cells and bundles them up as triglycerides, which are then sent out to the rest of your
body to use as fuel.
There is some controversy relating around high triglyceride levels and if they alone
are the cause for heart disease. The reason for this debate is that many people having
high LDL and low HDL also have high triglyceride levels. Other health conditions
related to high triglycerides include high blood pressure, obesity, diabetes, chronic
kidney and liver circulatory disease, and hypothyroidism.
Research shows that you can lower your triglycerides without the use of medication
although that is an option if needed or prescribed by your doctor.
Triglycerides (VLDL) Treatment
Triglyceride is a fatty substance that is composed of three fatty acids. Like
cholesterol, triglycerides in the blood either comes from the diet or the liver. Also,
like cholesterol, triglyceride cannot dissolve and circulate in the blood without
combining with a lipoprotein. Thus, after a meal, the triglyceride and cholesterol
that are absorbed into the intestines are packaged into round particles called
chylomicrons before they are released into the blood circulation. A chylomicron is a
collection of cholesterol and triglyceride that is surrounded by a lipoprotein outer
coat. (Chylomicrons contain 90% triglyceride and 10% cholesterol.)
The liver removes triglyceride and chylomicrons from the blood, and it synthesizes
and packages triglyceride into VLDL (very low-density lipoprotein) particles and
releases them back into the blood circulation.
The elevated triglyceride levels in the blood lead to atherosclerosis and heart attacks
remains controversial. While most doctors now believe that an abnormally high
triglyceride level is a risk factor for atherosclerosis, it is difficult to conclude that
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elevated triglycerides by themselves cause atherosclerosis. However, it is
increasingly recognized that elevated triglyceride is often associated with other
conditions that increase the risk of atherosclerosis, including obesity, low levels of
HDL- cholesterol, insulin resistance and poorly controlled diabetes mellitus, and
small, dense LDL cholesterol particles.
In some people, abnormally high triglyceride levels (hypertriglyceridemia) are
inherited. Examples of inherited hypertriglyceridemia disorders include mixed
hypertriglyceridemia, familial hypertriglyceridemia, and familial
dysbetalipoproteinemia.
Hypertriglyceridemia can often be caused by non-genetic factors such as obesity,
excessive alcohol intake, diabetes mellitus, kidney disease, and estrogen- containing
medications such as birth control pills.
Treating Elevated Blood Triglyceride Levels
The first step in treating hypertriglyceridemia is a low fat diet with a limited amount
of sweets, regular aerobic exercise, loss of excess weight, reduction of alcohol
consumption, and stopping cigarette smoking. In patients with diabetes mellitus,
meticulous control of elevated blood glucose is also important.
When medications are necessary, fibrates (such as Lopid), nicotinic acid, and statin
medications can be used. Lopid not only decreases triglyceride levels but also
increases HDL cholesterol levels and LDL cholesterol particle size. Nicotinic acid
lowers triglyceride levels, increases HDL cholesterol levels and the size of LDL
cholesterol particles, as well as lowers the levels of Lp (a) cholesterol.
The statin drugs have been found effective in decreasing triglyceride as well as LDL
cholesterol levels and, to a lesser extent, in elevating HDL cholesterol levels. A
relatively new medicine, fenofibrate (Tricor), shows promise as an effective agent in
lowering serum triglyceride levels as well as raising HDL levels, particularly in
patients who have had suboptimal responses to Lopid. In some patients, a
combination of Lopid or Tricor with adjunctive statin therapy (see below) may be
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prescribed. While this combination is often effective in patients with complex lipid
disorders, the potential for side effects may be increased and such patients should be
under strict medical supervision.
Blood Cholesterol Levels:
In order for your doctor to know your cholesterol level, a blood sample must be
taken from your finger or your arm. The blood sample will be tested for total
cholesterol and HDL cholesterol levels.
If your total cholesterol is less than 200 mg/dl and your HDL-cholesterol ("good"
cholesterol) is 40 mg/dL.
Cholesterol Levels - Risk Factors:
A plethora of things can affect cholesterol levels. Some of them which you have
control over cholesterol levels include: Diet, Weight, & Physical Activity.
Diet: Cholesterol in the food and the saturated diet you eat make your blood
cholesterol level go up. Saturated fat is the primary concern but cholesterol in foods
also matters. The amount of saturated fat and cholesterol in your diet helps lower
your blood cholesterol level.
Weight: Being overweight is a risk factor for heart disease. It also tends to increase
your cholesterol. Losing weight can help lower your LDL and total cholesterol
levels, as well as raise your HDL and lower your triglyceride levels.
Physical Activity: Physical inactivity is ingredient to develop heart disease.
Consistent physical activity can help lower LDL (bad) cholesterol and raise HDL
(good) cholesterol levels. It also helps you lose weight. A minimum of 30 minutes of
physical exercise can be deemed sufficient if done on all days.
Cholesterol levels: Things beyond your control
Chapter 1                                                                                                    Introduction
Dept. of Pharmacology 28 JKK Nattraja College of Pharmacy
Age and Gender: Cholesterol levels rise as women and men get older. Before the
age of menopause, women have lower total cholesterol levels than men of the same
age. LDL levels tend to rise in women passing their age of menopause.
Heredity: High blood cholesterol can run in families. Your genes decide how much
amount of cholesterol your body makes.
In general, the higher your LDL level and the more risk factors you have (other than
LDL), the higher the LDL level, more risk factors you have and greater are your
chances of developing heart disease or having a heart attack. People having heart
disease are vulnerable for a heart attack. A combination of risk factors and people
with diabetes's are prone to heart attack.
Medications to Lower Cholesterol
Statins
 Atorvastatin
 Fluvastatin
 Lovastatin
 Pravastatin
 Rosuvastatin
 Simvastatin
Bile Acid Resins
 Cholestyramine
 Colestipol
 Colesevelam
Nicotinic Acid
 Niacin (Vitamin B3)
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Fibrates
 Clofibrate
 Fenofibrate
 Gemfibrozil
Lowering Cholesterol Levels
Drug therapy seems inevitable to people who after following a balance diet and
exercising to keep themselves fit, still suffer from high cholesterol levels. Although
we have medicines claiming to lower cholesterol, it still remains a matter of debate
among the various kinds of drugs.
People who need modern day medicine to try and stop high cholesterol levels, the
drugs of first choice for elevated LDL cholesterol are the HMG CoA reductase
inhibitors, e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and
simvastatin. Statin drugs are very effective for lowering LDL cholesterol levels and
have few immediate short-term side effects.
Drug consideration can be accounted for people with LDL cholesterol of 190 mg/dl
and without coronary heart disease with two or more other risk factors. The
objective is to bring it down to 130mg/dl. The same process is applied to persons
with LDL Cholesterol of 160mg/dl without coronary heart disease and with two
three other risk factors .The objective is to lower it down to 130mg/dl.
For persons with coronary heart disease with LDL Cholesterol of 130mg/dl, the
objective is to bring it down to 100mg/dl.
Precautionary Measures
In men less than 35 years of age and premenopausal women with LDL cholesterol
levels of 190 to 219 mg/dL, drug therapy should be delayed except in high-risk
patients such as those with diabetes. In coronary heart disease patients with LDL
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cholesterol levels of 100 to 129 mg/dL, the physician should exercise clinical
judgment in deciding whether to begin drug treatment.
In some cases, a physician may decide that using cholesterol-lowering drugs at
lower LDL cholesterol levels is justified. On the other hand, drug therapy may not
be appropriate for some patients who meet the above criteria. This may be true for
elderly patients.
Factors Influencing Cholesterol Lowering Drugs
 The presence of other coronary heart disease risk factors influences the use
of cholesterol-lowering drugs:
 Age (for men, 45 years or older; for women, 55 years or older OR premature
menopause)
 High blood pressure (140/90 mm Hg or higher)
 HDL cholesterol less than 40 mg/dL
 Family history of premature CHD (a father, brother or son with a history of
CHD before     age 55, OR a mother, sister or daughter with CHD before age
65)
 Smoking, living or working every day with people who smoke
 Diabetes (fasting blood sugar of 126 mg/dL or higher)
Managing Cholesterol Levels
Managing your cholesterol levels leads to a very healthy lifestyle. A few things have
to be done to get the desired results:
Exercise : Cutting down between 1,200 and 1,500 calories each week doing aerobic
exercise can have dramatic results. Exercising is a wonderful way to keep your heart
healthy, it also helps lose weight, which is an additional benefit. By losing excess
weight, you see significant increases in your HDL cholesterol."
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Avoid Trans Fatty Acids: Avoid Trans fatty acid containing foods such as French
fries, cookies, cakes and many of the fried fast foods.
Minimize Carbohydrates : Avoid sugar, flour, potatoes and white rice thus cutting
down on carbohydrates.. HDL level drops dramatically when blood sugar is spiked
by carbohydrates. Avoid Cholesterol Foods: Reduce food sources of cholesterol
such as egg yolk, liver, kidney, brains, etc.
Stop Smoking : According to a study, within just one week of quitting smoking,
HDL levels raised by seven points.
HYPERLIPIDEMIA
More than 650,000 people die every year of coronary heart disease (CHD) in
the US alone. In 1984 it was demonstrated for the first time that there exists a link
between serum cholesterol levels and risk to CHD. A 1% drop in serum cholesterol
reduces the risk for CHD by 2%. Positive risk factors for CHD include Age
(men>45 yrs, women>55 yrs); family history of premature CHD; smoking;
hypertension (>140/90 mm Hg); low HDL cholesterol (<35 mg/dl); obesity (>30%
overweight); diabetes; and high LDL (>160 mg/dl). Negative risk factors include
high HDL levels (>60 mg/dl). Major lipids found in blood stream are triglycerides,
phospholipids, cholesterol and cholesterol esters and free fatty acids. The function of
cholesterol is to help carry fat in the body, because fat being insoluble in water
cannot travel on its own in the blood stream. Cholesterol associates with fat and
protein and comes out of the liver as lipoprotein.
There are several types of lipoproteins for the transport of fatty material in
the body such as chylomicrons, very low density lipoproteins (VLDL), low density
lipoproteins (LDL), intermediate density lipoproteins (IDL) and high density
lipoproteins (HDL). Each has a different function in the transport system.
Hyperlipidemia, the elevation of lipid concentration in plasma, is the manifestation
of a disorder in the synthesis and degradation of plasma lipoproteins. Primary type
hyperlipidemia can be treated with drugs but the secondary type originating from
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diabetes, renal lipid nephritis or hypothyroidism demands the treatment of original
disease rather than hyperlipidemia. (Joel et al., 2001, and Sharma et al., 1997)
Classification of hyperlipidemia
Type I hyperlipidemia: It is characterised by high concentration of blood
chylomicrons. Currently there are no drugs available for treating this type.
Type II hyperlipidemia: It is sub divided into Type II-A hyperlipidemia and Type
II-B hyperlipidemia. Type II A hyperlipidemia is characterized by high LDL and
cholesterol levels with a slight increase in blood triglycerides. Type II B
hyperlipidemia is characterized by the elevation of triglycerides, serum cholesterol,
LDL and VLDL.
Type III hyperlipidemia: This condition results when there are elevated levels of
triglycerides and IDL. A blockade in the normal conversion of VLDL to LDL results
in accumulation of IDL. Controlled diet is the treatment of this type of
hyperlipidemia.
Type IV hyperlipidemia: It is the sequel to high concentration of triglycerides and
VLDL and often faulty carbohydrate metabolism. Both diet and drug therapy is
recommended for this type of hyperlipidemia.
Type V hyperlipidemia: It shows elevated levels of chylomicrons, VLDL and
triglycerides resulting from faulty carbohydrate metabolism.
A major concern in patients with hyperlipidemia is the increased risk of
atherosclerosis resulting in heart diseases. The aim of treating the patients with
hyperlipidemia is to reduce serum cholesterol and/or improve the HDL cholesterol
by maintaining a high ratio of HDL to LDL cholesterol level thereby reducing the
risk of developing heart diseases. (Nanjaian Mahadevan et al., 2007)
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Mechanism of Lipid Transport
Dietary fat including cholesterol and triglycerides are absorbed in the
intestine and released in the blood stream as chylomicrons. These are least dense
particles having very high proportion of triacylglycerides. Lipoprotein lipase acts on
these particles to release some free fatty acids that deposit in adipose tissues. The
remnants of chylomicrons are picked up by the liver which has a receptor specific to
chylomicron remnants. After further clean up liver releases particles called the very
low density lipoproteins (VLDL) in the blood. These have lower triacyl glycerides
than chylomicrons. Once again LPL works on these VLDL particles releasing more
free fatty acids and changing the content of the particles to IDL and LDL. There are
LDL receptors on the cell membranes of the extra hepatic cells which can pick up
the LDL particles. This is how cholesterol reaches the interior of normal cells.
Within cells, LDL particles are repackaged. Excess cholesterol is esterified and
stored. Excess cholesterol suppresses the biosynthesis of LDL-receptors so that
intake of cholesterol decreases. It also suppresses cholesterol biosynthesis.
Repackaged LDL particles called HDL particles are then released into the blood
stream. These particles are sensed by the liver through the HDL-receptors. Thus the
liver gets constant information as to how much LDL and HDL are present in the
blood.(Umesh R Desai, 2000)
Figure No. 3
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Strategies for treating Hyperlipidemia
Figure No. 4
Statins
Statins inhibit the rate-limiting step in the biosynthesis of cholesterol - HMG
-CoA reductase. Decreased cholesterol biosynthesis steps up the levels of the LDL-
receptor resulting in the positive cycle for lowered cholesterol levels in serum. For
patients who have familial hypercholesterolemia due to defective LDL-receptor
genes these drugs are not effective. Statins are most effective cholesterol lowering
drugs. Statins lower total cholesterol and LDL particles. These are competitive
inhibitors. The HMG-CoA has a conformation similar to the lactone moiety of
statins resulting in binding at the same site without any productive effect.
All statins are highly protein bound (95-98%) except for pravastatin (50%, due
to carboxylate moiety). Most statins have a short half-life of about 1-3 hr except for
atorvastatin which has a 1/2 of about 14 h. A 15-30 point drop in LDL could be
reasonably expected with most statins after a therapy of about 1 month. A
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combination therapy (with bile acid sequestering agents) is helpful for particularly
difficult cases. Although possible, statins typically do not affect the concentrations
of steroid hormones in circulation.
Fibrates
Gemfibrozil was introduced in 1981 and remains the second most useful
antilipidemic agent. It primarily decreases serum triglycerides. Newer drugs
including beclofibrates, ciprofibrates, fenofibrates, are more effective in lowering
serum LDL cholesterol. However, the fibrates are almost never used alone. They are
mostly used in combination with bile acid sequestering agents.
The antitriglycedemic effect of clofibrate in human is related to the
increased catabolism of serum TG-rich proteins (VLDL and VLDL remnants), but
not to any effect on hepatic TG or VLDL synthesis and release from liver. The
action of clofibrate is related to an increase in adipose tissue or muscle LPL activity
which accelerates the rate of intravascular catabolism of VLDL to IDL and LDL.
Clofibrate is metabolized to chlorophenoxyisobutyric acid (CPIB) which is
the active form of the drug. The drug is high protein bound with a half-life of around
15 hrs.
Bile Acid Sequestering (BAS) Agents
Colestipol and cholestyramine are anion exchange resins that are approved
in 1970s for the reduction of elevated serum cholesterol in patients with
hypercholesterolemia. These resins are water insoluble, inert to digestive enzymes in
the intestinal tract and are not absorbed. Both resins are quaternized at stomach pH
and exchange anions for bile acids dramatically reducing the reabsorption of bile
acids. The liver senses that bile acid concentrations have gone down and hence turns
on cholesterol metabolism. Serum HDL and TG levels remain unchanged. LDL
levels are found to decrease.
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The fall in LDL concentration is apparent in 4 to 7 days. The decline in
serum cholesterol is usually evident by 1 month. When the resins are discontinued,
the serum cholesterol usually returns to baseline within a month. When bile acid
secretion is partially blocked, serum bile acid concentration rises. For these patients,
cholestyramine reduces bile acid deposits in the dermal tissues. One of greatest
advantage of these polymeric agents is that they can be safely used for pregnant
women. However, exercise caution for nursing women because presence of these
cationic polymeric agents in the GI tract might lower the absorption of vitamin D.
BAS agents may also lower the amount of anticoagulants (warfarin, Coumadin)
absorbed due to sequestration.
Nicotinic Acid
Pharmacologic doses of nicotinic acid reduce serum cholesterol and TG
levels in types II, III, IV, and V hyperlipoproteinemias. TG and VLDL are reduced
by 20 to 40% in 1 to 4 days; LDL reduction may be seen in 5-7 days. The decrease
in LDL is usually greater if niacin is used with a BAS resin. HDL is increased by
20%. The exact mechanism is unknown. It is known that niacin decreases lipolysis
in adipose tissue, decreases TG esterification in the liver and increase LPL activity.
Niacin is rapidly absorbed. (Umesh R Desai, 2000)
Plant remedies for Hyperlipidemia
A number of plant preparations such as Allium sativum, Cicer arientinum, Inula
recemosa, Terminalia arjuna, Trigonella foenum graecum, Commiphora mukul,
green tea and curcumin have been reported to have hypolipidemic actions. Few of
these also, possess certain other beneficial properties like antianginal and antiplatelet
actions. Plant preparations contain many compounds that work synergistically on
multiple parts of the body. For example, garlic is not only antibacterial, but
antifungal, and helps to lower cholesterol. This synergy of chemicals helps to
balance the overall activity of the herb. Since the chemicals in herbs are non-specific
and unconcentrated, there are generally fewer side effects from herbs than from
manufactured drugs. Further, according to a study published in the April 15, 1998
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issue of the Journal of the American Medical Association, the fifth leading cause of
death in the United States in 1994 was adverse drug reactions of modern medicine,
an excess of 100,000 deaths. By contrast, there have been less than 100 adverse
reactions and only one death attributed to herbs in Canada since 1990. Most
reactions to herbs have to do with an individual allergic reaction to the herb or to an
interaction with prescription drugs.
Table no. 2
Sl.No Name of Plant Family Common/ Indian
vernacular names Plant parts
1 Aegle marmelos Rutaceae Beal fruit, bilwa Fruits
2 Agave Veracruz Amaryllidaceae American aloe,
barakhawar
Roots, leaves,
gum
3 Allium cepa Lilliaceae Onion, piyaj, palandu Bulbs
4 Aloe barbadensis Lilliaceae Ghee kumar,
gwarpatha
Leaves
5 Bambusa
arundunacea
Graminae Bamboo vamsha Leaves
6 Bosswellia serrata Burserraceae Salai guggal Gum
7 Brassicavercapitata Cruciferae Cabbage Oil
8 Cajanus cajan Fabaceae Red gram Seeds
9 Capparis decidua Capparaceae Karli, tint Leaves, fruits
and stems
10 Capsicum frutescens Solanaceae Chillies Fruits
11 Carum capaticum Umbelliferae Jowan, ajowan Fruits, roots
12 Celastrus
paniculatus
Celastraceae Khunjri, kusur Seed oil, barks,
roots and fruits
13 Curcuma amada Zingiberaceae Mango ginger, haridra Rhizomes
14 Cyamopsis
tetragonoloba
Leguminosae Guar, gwar Seeds
15 Emblica officinalis Euphorbiaceae Amla, amlki Dried fruits,
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Seeds, leaves
16 Eugenia cumini Myrtaceae Jamun Seeds
17 Inula racemosa Compositae Puskarmul Roots
18 Juglans regia Juglandaceae Walnut, akhrot Kernel, oil
19 Medicago sativum Papilionaceae Alfalfa Seeds
20 Momordica
charantia
Cucurbitaceae Bitterground, Fruits
21 Musa saspientum Musaceae Banana, kela Roots,Stems,
Flowers, Fruits
22 Nepeta hindostana Labiatae Billiola, badranj boya Whole plant
23 Phaseolus aureus Fabaceae Green gram Seeds
24 Phaseolus mungo Fabaceae Black gram Seeds
25 Pergularia daemia Asclepidaeceae Veliparutti, Uttravani Whole plant
26 Piper nigrum Piperaceae Golmirch, kalimich Leaves
27 Pisum sativum Papilionaceae Gardenpea, matar Seeds
28 Pterocarpus
marsupium
Papilionaceae Indian malabarkino Gum and
leaves
29 Saussuraea lappa Asteraceae Kustha, Kut Roots
30 Terminalia arjuna Combretaceae Arjun Barks
FLAVONOIDS, LIPIDS AND LIPOPROTEINS
The lipid lowering properties of flavonoids have been evaluated.
Dyslipidemia is characterized by hepatic over secretion of Apo BIOO-containing
lipoproteins, hypertriglyceridemia, delayed clearance of LDL and low levels of
HDL. Dietary studies in humans have demonstrated the beneficial effects of many
flavonoids including those contained in soy protein isolate and green tea, both of
which lower LDL cholesterol. However, studies with anthocyanidins, black tea,
chocolate, red wine and grape demonstrated no beneficial effects on LDL-C or
HDL-C in human studies. However, both animal and human studies have
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demonstrated that mixtures of specific bioactive flavonoids can decrease LDL-C.
Treatment of fructose-induced, insulin-resistant hamsters with a mixture of citrus
polymethoxylated flavones improved dyslipidemia and glucose tolerance. However,
the mechanism was not elucidated.
Berberine, an alkaloid isolated from Chinese herbs, up-regulated LDL
receptor expression in cultured hepatocytes through a MAPKerk dependent
mechanism and reduced plasma lipids in a hyperlipidemic hamster model.
Administration of berberine to hypercholesterolemic patients reduced LDL
cholesterol by 25%, demonstrating the cholesterol lowering potential of berberine in
humans.
FLAVONOIDS AND ATHEROSCLEROSIS
The early stages of atherosclerosis are characterized by endothelial
dysfunction and macrophage foam cell formation. Administration of pomegranate
juice, rich in anthocyanidins and proanthocyanidins to apolipoprotein E-deficient
(apoE1') mice resulted in dramatic reductions in lipid peroxides and macrophage CE
accumulation, without significantly affecting plasma cholesterol. Following 3
months of supplementation, atherosclerosis was significantly reduced.
Administration of pomegranate by-product (PBP) to apoE^mice also attenuated
atherosclerosis development, as a result of decreased cellular uptake of oxidized
LDL and macrophage oxidative stress. Using the same apoE1' mouse model, 4
month supplementation of a low fat diet with the polyphenolic compound resveratrol
led to a reduction in total plasma cholesterol and LDL-C and an increase in HDL-C.
The mechanism for the reduction in plasma cholesterol was through a reduction in
hepatic cholesterol synthesis, which may have stimulated LDL receptor mediated
uptake of LDL from plasma. Resveratrol also prevents lipid peroxidation and
increases the cholesterol efflux from macrophages through these mechanisms,
resveratrol significantly reduced atherosclerotic plaque development in the aortic
arch of apoE1' mice.
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REVIEW OF LITERATURE
PLANT PROFILE
Classification
Kingdom - Plantae – Plants
Subkingdom - Tracheobionta – Vascular plants
Division - Magnoliophyta – Flowering plants
Class - Magnoliopsida – Dicotyledons
Order - Gentianales
Family - Asclepiadaceae – Milkweed family
Genus - Pergularia L. – pergularia
Species - Pergularia daemia (Forssk.) Chiov. – Pergularia
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Synonyms :   Asclepias daemia, Daemia extensa, Cynanchum extensum
Vernacular names
English : Hariknot plant
Hindi : Utaran, Sagovani, Aakasan, Gadaria Ki bel, Jutak
Marathi : Utarn
Tamil : Uttamani, Seendhal kodi
Malayalam        : Veliparatti
Telugu               : Dustapuchettu, Jittupaku
Kannada           : Halokoratige, Juttuve, Talavaranaballi, Bileehatthi balli
Sanskrit            : Uttamarani, Kurutakah, Visanika, Kakajangha
Description
Pergularia is a perennial twining herb, foul-smelling when bruised and with much
milky juice, stem hairy. Leaves are thin, broadly ovate, heart-shaped or nearly
circular, hairless above, velvety beneath. Greenish yellow or dull white, and
sweet-scented flowers are borne in lateral cymes which are at first corymb-like,
afterwards raceme-like. The five petals are hairy and spreading outwards. Corona
outer and inner, outer truncate, inner curved high over the staminal column, spur
acute. Fruit is a follicle, with soft spines all over and a long beak. Seeds are
densely velvety on both sides.
Flowering: August-February.
ORIGIN
The cultivated form is thought to be African in origin, from where it was
introduced to practically all temperate regions of the world.
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PARTS USED
Leaves, latex from the plant, roots and whole plant are used.
ACTIVE INGREDIENTS
The active ingredients in Pergularia daemia are cardenolides, alkaloids,
triterpenes and saponins.
PHARMACOLOGICAL EFFECTS
The plant has been demonstrated to possess multiple pharmacological
activities such as antiinflammatory, hepatoprotective, anticancer, antidiabetic,
antioxidant, antibacterial, antifungal, analgesic, antiinfertility and central nervous
system depressant activity. This review highlights on the existing information
particularly on the phytochemistry and various pharmacological properties of
Pergularia daemia which may provide incentive for proper evaluation of the plant
as a medicinal agent.
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Structures and activities of some active compounds from Pergularia daemia
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MEDICINAL USES
In ayurvedic system of medicine this plant is used for delayed child
birth, amenorrhea, asthma, snake bite, rheumatic swellings and also to treat post-
partum hemorrhage. The decoction of the plant (10-20 mL) is also applied on
white spots (leucoderma). Leaf decoction is an uterine tonic and is taken orally up
to 20 mL day-1. The stem and root bark extract is taken against fever and
diarrhea in infants. The leaves are specially used as a condiment for soup and
porridge yam. Fruits are digestive and thermogenic. Plant extract is useful in
uterine and menstrual disorders and in facilitating parturition. Pergularia has been
used in folk medicine for the treatment of liver disorders. Traditionally used in
treating various ailments for human beings. Some of the folklore people used this
plant to treat jaundice, anthelmintic, laxative, anti-pyretic, expectorant and also
used in infantile diarrhoea.
LITERATURE SURVEY
 Lokesh T Nikajoo et al., 2009 investigated the analgesic activity of
aqueous and alcohol root extracts of Pergularia daemia (Forsk.) Chiov.
For the evaluation of analgesic activity of analgesic activity of aqueous
and alcohol root extracts of Pergularia daemia (Forsk.) Chiov. Using
eddy’s hot plate and heat conduction method. In eddy’s hot plate method
the aqueous extract showed significant analgesic activity at the doses of
500 mg/kg (p<0.01) and 1000 mg/kg (p<0.001) and alcohol extract
showed significant analgesic activity at the doses of 500 and 1000 mg/kg
(p<0.001). In heat conduction method both extracts showed significant
analgesic activity at the doses of 500 & 1000 mg/kg (p<0.001) as
compared to control group, when analysed statistically by Tukey Kramer
Multiple Comparison Test. The result obtained show that the aqueous and
alcohol root extracts of Pergularia daemia (Forsk.) Chiov. Possesses
significant analgesic activity.
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 Raman R Chandak et al., 2010 investigated the  Antibacterial activity of
Chloroform and Ethanol extracts of Whole Plant of Pergularia daemia
Linn. Were tested cup-plate agar diffusion method against Gram positive
and Gram negative bacteria. It was observed that all extracts have
inhibitory effect, water extract being most effective.
 Golam sadik et al., 2001 investigated the antifertility activity of ethonalic
and its steroidal fraction of Pergularia daemia (Forsk.) Chiov. Both the
ethanol extract and the steroidal fraction showed significant antifertility
activity in the pre implantation stage in female mice.  The ethanol extract
showed late abortificient effect.
 Suresh M et al., 2010 investigated the antifungal activity of the salts from
five Indian medicinal plants against three human pathogenic fungi.
Antifungal assay was done using agar disc diffusion method. The result
showed that the plat salt of Indian medicinal plants i.e. Acalypha indica,
Centella asiatica, Aerva lanata, Clerodendrum inerme, Pergularia daemia,
Solanum melongena exhibited significant antifungal activity against one
or more test organism.
 S.Venkataraman et al., 2010 investigated the analgesic, antipyretic and
anti-inflammatory of Petroleum ether and Chloroform extract of plant of
Pergularia daemia Forsk were studied .The analgesic activity was found
out by eddy’s hot plate method by using standard Diclofenac sodium .
The antipyretic activity was found out by yeast induced pyrexia method
by using standard Paracetamol. The anti-inflammatory activity was found
out by Carragenan induced paw edema method by using standard
Diclofenac sodium. In carrageenan induced paw odema method the
chloroform extract of Pergularia daemia showed more significant
inhibition than petroleum ether extract. The results were found to be
highly significant (p<0.01) in comparison to the control. In eddy’s hot
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plate method the chloroform extract of Pergularia daemia exhibited
significant analgesic activity than petroleum extract. In antipyretic activity
the chloroform and pet ether both extracts having significant activity.
 V. M. Shastry et al., 2011 investigated the acute and chronic
anti‐inflammatory activity of petroleum ether extract (PDPE), ethanolic
extract(PDEE) and aqueous extract(PDAE) of whole plant of Pergularia
daemia (100, 200 and 400 mg/kg) have been investigated in carrageenan‐
and formalin‐ induced paw edema and turpentine oil‐induced granuloma
pouch in rats. Oral administration of PDEE (200 and 400 mg/kg)
significantly reduced the paw volume (P <0.001) at 3h in carrageenan
model. The treatment of PDEE (200 and 400 mg/kg) significantly reduced
the volume of exudates (P <0.001) in turpentine oil‐induced granuloma
pouch dose dependently. Chronic inflammation induced by formalin
injection was significantly (P <0.001) inhibited by PDEE (400 mg/kg) as
compared to the control rats. Diclofenac (10 mg/kg) was used as reference
drug. Thus, the present study shows that whole plant of Pergularia daemia
possess significant anti‐inflammatory activity and supports the claim in
traditional medicine for the treatment of inflammatory conditions.
 Hariram V Bhaskar et al., 2009 investigated the  antioxidant and free
radical scavenging properties of the ethanol and aqueous extracts from
roots of Carissa carandas and Pergularia daemia in various in vitro
systems. Reducing power, DPPH radical, superoxide radical, nitric oxide
radical and hydrogen peroxide radical scavenging assays were carried out
to evaluate the antioxidant potential of the ethanol and aqueous extracts
from roots of C. carandas and P. daemia. Total phenolic content and total
flavonoids were also evaluated. In the DPPH radical scavenging assay
theIC50 values were 178.84 and 169.39 μg/ml for ethanol extract of C.
carandas and P. daemia respectively. In the nitric oxide radical scavenging
assay the ethanol extract of P. daemia showed maximum percentage
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inhibition (65.14±0.0115), while the aqueous extract of P. daemia
exhibited least percentage inhibition(62.69±0.0461) on superoxide radical
scavenging, when compared with other extracts. The aqueous extract of
C. carandas and P. daemia exhibited 50%scavenging activity at 208.07
and 243.09 μg/ml on H2O2 radical. The reducing power of the extracts
increased dose dependently. All the extracts exhibited significant
antioxidant (p< 0.01) activity. The extracts of the roots of C. carandas and
P. daemia possess antioxidant properties and could serve as free radical
inhibitors or scavengers.
 Te Khorombi et al., 1997 investigated the methanol–dichloromethane
(1:1 v/v) extract of the whole plant Pergularia daemia  inhibited the
growth of the cancerous cells when tested both at the CSIR and NCI.
Repeated flash chromatography of the organic extract afforded the
isolation of five compounds that were characterized as β-sitosteryl
glucoside, β-sitosterol, α-amyrin, 3-O-acetyl-α-amyrin and a disaccharide,
sucrose. These compounds showed no significant anti-cancer activity
against the CSIR’s three cell lines, except α-amyrin that exhibited low
potency. Furthermore, substitution of the hydroxyl group at position 3 of
α-amyrin with the acetate functionality resulted in loss of activity. This
finding suggests that the presence of the hydroxyl group at position 3 is
important for the inhibition of the growth of cancer cells.
 Manickam Pavunraj et al., 2010 investigated the leaves of milkweed,
Pergularia daemia (Forssk) Choiv., on the antifeedant activity against two
important lepidopteran pests, Helicoverpa armigera (Hub.) and
Spodoptera litura (F.), were studied. Maximum antifeedant activity was
recorded in ethyl acetate crude extract against H. armigera (70.3%) and S.
litura (71.82%) at 1% concentration. Ethyl acetate crude extract was
further subjected to column chromatography, which was performed using
hexane as initial solvent and then by increasing the polar strength using
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ethyl acetate. Fractions collected at hexane and ethyl acetate (80:20)
yielded 6-(4,7-hydroxy-heptyl) quinone, a novel compound which showed
significant antifeedant activity against H. armigera (80.22% at 2000 ppm)
and S. litura (68.31% at 2000  ppm).
 BA Vyas1 et al., 2011 investigated The whole-plant, Pergularia daemia
(Family: Asclepediaceae), extract (50% alcohol)  for its antiurolithiatic
and diuretic activity. Ethylene glycol (0.75% in water) feeding resulted in
hyperoxaluria as well as increased renal excretion of calcium and
phosphate. Alcoholic extract (400 mg/kg) of P. daemia was given orally
in curative and preventive regimens over a period of 28 days.
Supplementation with extract significantly (P < 0.001) lowered the
urinary excretion and kidney retention levels of oxalate, calcium and
phosphate. Furthermore, high serum levels of urea nitrogen, creatinine
and uric acid were significantly (P < 0.001) reduced by the extract. The
results were comparable with the standard drug, cystone (750 mg/kg). The
reduction of stone-forming constituents in urine and their decreased
kidney retention reduces the solubility product of crystallizing salts such
as calcium oxalate and calcium phosphate, which could contribute to the
antiurolithiatic property of the extract. The extract exhibited significant
diuretic activity at dose of 400 mg/kg body weight as evidenced by
increased total urine volume and the urine concentration of Na +, and K +
. These findings affirm assertions made regarding the effectiveness of the
extract of this plant against urinary pathologies in the Indian folk
medicine.
 G.Ramu et al., 2009 investigated the  Root starch (14.0% w/w) obtained
from Pergularia daemia  was employed as a disintegrant to paracetamol
tablets at concentrations of 2.5-10.0 % w/w in the present study. The limit
tests, loss on drying, ash value and microbial load were well within the
official limits. The starch was also evaluated for various parameters as per
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Indian Pharmacopoeia. The granules prepared by wet granulation
technique were evaluated for percentage of fines, bulk and tapped
densities and flow properties. Tablet properties including thickness,
content uniformity, average weight and weight variation, hardness,
friability, disintegration time and drug dissolution were evaluated. The
disintegrant efficiency of extracted starch was compared with that of the
corn starch in tablets prepared using magnesium stearate, aerosil,
microcrystalline cellulose and gelatin as lubricant, glidant, diluent and
binder respectively. The disintegration time for tablet formulations
prepared using 10 % w/w extracted starch was less (166 s) than that of the
tablet formulations prepared using corn starch as a disintegrant (270 s).
Dissolution studies showed that the drug release from the tablet
containing 2.5 to 10 % w/w was more than 60 % in 1hr. Studies indicated
that Pergularia daemia starch is a good disintegrant in tablet formulation.
 Suresh kumar et al., 2007 investigated the hepatoprotective activity of
ethonalic and its ethanol fraction of Pergularia daemia plant aerial parts
exhibited significant hepatoprotective effect against CCl4 induced
hepatotoxicity in rats. Glutamic oxaloacetic transaminase, glutamic
pyruvic transaminase, alkaline phosphatase, total bilirubin, total
cholesterol, total protein and albumin in serum indicated hepatoprotective
effect of the ethanol extract and its ethanol fraction. Histopathological
examination of liver sections confirmed that, pre-treatment with ethanol
extraction and its ethonalic fraction prevented hepatic damage induced by
CCl4. The results were comparable with the standard hepatoprotective
drug Silymarin. The extract and its fraction showed no signs of toxicity up
to a dose level of 2000 mg/kg. It is suggested that, the presence of
flavonoids in ethanol extraction and its ethonalic fraction may be
responsible for hepatoprotective properties. HPTLC profile of flavonoids
of bio active extracts was developed using quercetin-3-glycoside as
marker. Results indicate hepatoprotective properties of ethanol extract of
Pergularia daemia.
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 Varsha Dhulasavant et al., 2011 investigate the hypolipidemic effect of
Cinnamomum tamala Nees. Leaves extracts in high cholesterol diet
induced hyperlipidemia. Aqueous and ethanolic extracts of leaves of
Cinnamomum tamala Nees. were administered in doses of 400mg/kg /day
p.o. each for 10 days. Simultaneous administration of Cinnamomum
tamala Nees. leaves extracts significantly(p<0.001) prevent the rise in
serum levels of total cholesterol, triglyceride, LDL-C,VLDL-C and
atherogenic index whereas significant (p<0.01) increases in the level of
HDL-C.
 W.C. Lee et al., 2001 investigated the  Effects of high-cholesterol diet on
the interendothelial clefts and the associated junctional complexes in rat
aorta. The arterial endothelial intercellular cleft (AEC) and its associated
junctional complex (JC) are the determinants of permeability to
macromolecules. This study analyzed frequencies of AEC and JC profile
types in the rat thoracic aorta at 1 and 12 months after feeding the animals
with a normal or a high-cholesterol diet. Rats on either a normal diet or
high-cholesterol diet for 12 months showed more of the simple ‘end to
end’ or ‘overlap’ types (PB0.01) but fewer complex ‘interdigitating’ type
(PB0.01) of AEC compared to the 1 month group. With regard to JC, the
frequencies of gap junctions were decreased (PB0.01) while the tight
junctions and the normal junctionless complex were increased (PB0.01)
after 12 months of normal diet as compared with 1 month on the normal
diet. These changes in frequencies for gap junction and tight junction
were even greater for the high-cholesterol diet than for the normal diet
treatment. Moreover, the incidence of open junctions was also noticeably
increased after 12 months of high-cholesterol diet. These findings suggest
that the proportions of the AEC and JC were highly responsive to aging
whereas those of JC were more susceptible to the high-cholesterol diet
treatment.
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 Bhalodia Yagnik et al., 2009 investigated the antihyperlipidemic and
antioxidant activity of methanolic fruit extract of Benincasa cerifera in
high fat diet induced hyperlipidemic rat. Wistar albino rats were fed with
high fat diet containing 2% cholesterol and 20% coconut oil for 4 weeks
and serum cholesterol level were measured every week. At the end of
third week methanolic extract of Benincasa cerifera fruit (500 mg/kg/day)
was administered orally for 1 week. At the end of fourth week, the serum
lipid metabolites such as total cholesterol, triglycerides and high density
lipoproteins were determined. In order to determine antioxidant activity of
extract, renal tissues were homogenized in ice cold saline buffer and the
assay of lipid peroxidation, superoxide dismutase, reduced glutathione
and catalase were performed in control, hyperlipidemic and treated rats.
High fat diet feeding rat for 4 weeks shows significant difference in lipid
metabolites, lipid peroxidation and antioxidant enzymes level when
compared with normal control rat. Oral administration of Benincasa
cerifera for one week resulted in a significant reduction in total
cholesterol and triglyceride level, and significant improvement in lipid
peroxidation, superoxide dismutase and reduced glutathione in renal
tissues of hyperlipidemic rats when compared with hyperlipidemic control
rat. The Benincasa cerifera showed significant antihyperlipidemic and
antioxidants activity in hyperlipidemic rat.
 Si-Yuan Pan et al., 2009 investigated the Effects of the ethanol extract of
Fructus Schisandrae (EtFSC) on serum and liver lipid content in mice fed
with high fat/cholesterol (HFC) diet for 8 or 15 days. The induction of
hypercholesterolemia by HFC diet caused significant increases in serum
and hepatic total cholesterol (TC) levels (up to 62% and 165%, resp.) and
hepatic triglyceride (TG) levels (up to 528%) in mice. EtFSC treatment (1
or 5 g/kg/day for 7 days; from Day 1 to 7 or from Day 8 to 14, i.g.)
significantly decreased the hepatic TG level (down to 35%) and slightly
increased the hepatic index (by 8%) in hypercholesterolemic mice.
Whereas fenofibrate treatment (0.1 g/kg/day for 7 days, i.g.) significantly
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lowered the hepatic TG level (by 61%), it elevated the hepatic index (by
77%) in hypercholesterolemic mice. Acute toxicity test showed that
EtFSC was relatively non-toxic, with an LD50 value of 35.63 ± 6.46 g/kg
in mice. The results indicate that EtFSC treatment can invariably decrease
hepatic TG in hypercholesterolemic mice, as assessed by both preventive
and therapeutic protocols, suggesting its potential use for fatty liver
treatment.
 Vincenzo et al., 2010 investigated Bergamot juice produces hypolipemic
activity in rats though the mechanism remains unclear. Here we
investigated on the effect of bergamot extract (BPF) in diet-induced
hyperlipemia in Wistar rats and in 237 patients suffering from
hyperlipemia either associated or not with hyperglycaemia. BPF, given
orally for 30 days to both rats and patients, reduces total and LDL
cholesterol levels (an effect accompanied by elevation of cHDL),
triglyceride levels and by a significant decrease in blood glucose.
Moreover, BPF inhibited HMG-CoA reductase activity an enhanced
reactive vasodilation thus representing an efficient phytotherapeutic
approach in combating hyperlipemic and hyperglycaemic disorders.
 Gloria A. Otunola1 et al., 2010 investigated the effects of a high dietary
soybean oil and cholesterol on serum total cholesterol, low density
lipoprotein (LDL-C), high density lipoprotein (HDL-C), and triglycerides
were investigated. Total protein, albumin, glucose, gamma glutamyl
transferase (GGT), aspartate aminotransferase (AST) and alanine amino
transferase (ALT) activities were also investigated in weanling female
Wistar rats for eight weeks. Two groups of weanling Wistar rats were use
in this study. The first group of rats were fed with a control diet made up
of the normal rat chow (C), while the second group was given a
hypercholesterolemic diet (HPC) enriched with 25% soybean oil and 1%
cholesterol for eight weeks. The dietary intake of the HPC diet
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significantly increased the level of total cholesterol, LDL-C and
triglycerides in the serum of animals fed the (HPC) diet. GGT, AST and
ALT activities were also markedly elevated in rats fed with the HPC diet.
While total protein and glucose level of the animals fed with the HPC diet
was remarkably reduced, there was no significant difference in the HDL-
C and albumin contents of both groups. This study established that
hypercholesterolemia is induced by high soybean oil/cholesterol diet,
despite the fact that soybean oil has high content of poly unsaturated fatty
acids. Also, the HPC diet led to weight loss in the rats and injury to both
heart and liver of the rats.
 Mukesh Sikarwar et al., 2008 investigated the possible
antihyperlipidemic effect of petroleum ether (60-800C), chloroform,
ethanol and aqueous extracts of Nerium indicum leaves in triton
(400mg/kg b.w.) induced and atherogenic diet induced hyperlipidemic
rats. A comparison was also made between the action of Nerium indicum
leaves extracts and a known antihyperlipidemic drug simvastatin
(10mg/kg body wt.). Oral administration of 500 mg/kg body wt. of the
chloroform extract of Nerium indicum leaves exhibited a significant
reduction (p<0.01) in serum lipid parameters like total cholesterol,
triglycerides, low density lipoprotein (LDL), very low density
lipopreotein (VLDL) and increase in high density lipoprotein (HDL) in
hyperlipidemic rats in comparison with hyperlipidemic control in both
models.
 R P Umbare et al., 2009 investigated antihyperlipidemic effect of plant
Phyllanthus amarus Schumach against cholesterol diet induced
hyperlipidemia in Wister rats. Hydro-alcoholic extract of leaves of
Phyllanthus amarus Schumach (HAEPAS) was studied for its in-vivo
anti-hyperlipidemic potential using cholesterol diet induced
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hyperlipidemia model in rats. The result of study indicated that HAEPAS
possess significant hypolipidemic activity at doses 300 and 500 mg/kg.
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AIM AND OBJECTIVE
The main aim of the study is to evaluate the methonalic extract of
Pergularia daemia on rats fed with high fat diet.
Coronary artery disease (CAD) is one of the most important causes of
death all over the world. CAD remains the most common cause of morbidity and
mortality all over the world. In depending countries, the incidence of
cardiovascular disease is increasing alarmingly. India is on the verge of
cardiovascular epidemics. It is expected that the circulatory system disorders are
going to be the greatest killer in India by the end of year 2015. It is well
established increased levels of blood cholesterol especially low density
lipoprotein cholesterol (LDL-c) is an important risk factor for cardiovascular
complications since it favours lipid deposition in tissues including blood vessels.
Evidences from lipid lowering trials have clearly established that reduction of
total cholesterol or LDL-c is associated with decreased risk of atherosclerosis
and coronary heart disease. Furthermore, epidemiological studies have also
shown an inverse correlation between HDL cholesterol level and the risk of
CVD. A large number of allopathic hypolipidemic drugs are available in the
market but these lag behind the desired properties such as efficacy and safety on
long term use, cost and simplicity of administration.
Plant and plant products are being used as a source of medicine since
long. According to World Health Organization (WHO) more than 80% of the
world’s population, mostly in poor and less developed countries depend on
traditional plant based medicines for their primary healthcare needs. The
efficacy and safety of herbal medicine have turned the major pharmaceutical
population towards medicinal plant’s research. Owing to the global trend
towards improved ‘quality of life’, there is considerable evidence of an increase
in demand from medicinal plant. A number of medicinal plants have shown their
beneficial effect on the cardiovascular disease (CVD) by virtue of their lipid
lowering, antianginal, antioxidant and cardioprotective effects. The risk of
hyperlipidemia would be reduced by consumption of flavonoids and glycosides,
supported by abundant studies. For instance, the flavonoids extracted from
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gingko, soyabean, and some other plants have been beneficial to hyperlipidemia
patients. (Jing jing chen and Xian grong, 2007)
Traditionally the plant P.daemia is used as anthelmintic, laxative,
antipyretic and expectorant, also used to treat infantile diarrhoea and malarial
intermittent fevers. Latex of this plant used for toothache. Stem bark remedy for
cold and fever. Aerial parts of this plant reported the various harmacological
activities like hepatoprotective, antifertility, anti-diabetic, analgesic, antipyretic
and anti-inflammatory.
Pergularia daemia leaves contains various nutrient elements, such as
vitamins, minerals, carbohydrates, edible fibres and phytochemicals like
cardenolides, alkaloids and saponins and phenolic compounds. The plant was
found to contain various triterpenes and steroidal compounds.
Phenolic compounds from Pergularia daemia attracted the attention
of scientists to define their chemical composition and their properties for human
health. The reported evidences of beneficial health effects of phenolic compounds
include inhibiting some neurodegenerative diseases such as CVD, diabetes,
certain types of cancer. Considering the health benefits of phenolic compounds in
Pergularia daemia, it is planned to evaluate the lipid lowering effect on rat fed
with high fat diet (hypercholestreolemic rats).
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PLAN OF WORK
Collection
Collection of plant (Pergularia daemia) leaves and shade dried.
Extraction
Extraction of dried leaf powder using methanol in soxhlet apparatus for 72
hours.
Phytochemical investigation of methanol extract of Pergularia daemia.
Acute oral toxicity study of methanol extract of Pergularia daemia leaves.
Evaluation of anti-hyperlipidemic activity of  Pergularia daemia leaf extract  in rats
fed with high fat diet.
Screening method
Cholesterol Diet induced Hyperlipidemia in rats. ( Rumi Ghosh et al., 2010)
Biochemical estimation of serum lipid parameters
 Total cholesterol
 Serum HDL
 Serum LDL
 Serum VLDL
 Triglycerides
1. Histopathological study of liver.
2. Statistical analysis.
One way ANOVA followed by standard Dunnett’s test.
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MATERIALS AND METHODS
5.1 PLANT MATERIAL
The fresh leaves of Pergularia daemia were collected from local areas at
komarapalayam, Tamilnadu. The material was taxonomically identified, confirmed and
authenticated by Botanical survey of India (BSI) at TN agricultural university,
Coimbatore.
With authentication no BSI/SRC/5/23/2011-12/Tech.-1203 and the voucher specimen
was retained in our laboratory for further reference. The collected leaves were shade
dried and the dried material was crushed to coarse powder with mechanical grinder. The
powder was stored in air- tight container which was used for extraction.
5.2 PREPARATION OF EXTRACT
140 grams of powdered leaf material was defatted with petroleum ether (600-
800C) and then extracted with 95% methanol for 72 hrs using soxhlet apparatus. The
extract obtained was concentrated to dryness under reduced pressure and the percentage
yield was calculated.
5.3 CHEMICALS
Petroleum ether – Nice chemicals. Pvt Ltd, Cochin.
Methanol – Cheme pure Laboratory, Chennai.
CMC- Reachem Laboratory Chemicals Pvt Ltd, Chennai.
Cholesterol – Loba chemi laboratory Pvt Ltd, Mumbai.
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Sodium cholate -- Loba chemi laboratory Pvt Ltd, Mumbai.
All other chemicals and reagents were of the analytical grades.
5.4 PHYTOCHEMICAL SCREENING
The extract obtained was subjected to Priliminary Phytochemical screening.
5.4.1 Test for alkaloids
0.5gm of extract was dissolved in 10ml of dilute HCl (0.1N HCl) and filtered.
The filtrate was used to test the presence of alkaloids.
 Mayer’s test
Filtrate was treated with Mayer’s reagent. Formation of yellow cream precipitate
indicates the presence of alkaloids.
 Dragendroff’s test
Filtrate was treated with Dragendroff’s reagent. Formation of red colored
precipitate indicates the presence of alkaloids.
 Hager’s test
Filtrate was treated with Hager’s reagent. Formation of yellow colored
precipitate indicates the presence of alkaloids.
 Wagner’s Test
Filtrate was treated with wagner’s reagent. Formation of brown (or) reddish
brown precipitate indicates the presence of alkaloids. (Rosenthalar, 1930)
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5.4.2 Detection of Phytosterols and Triterpenoids
0.5gm of extract was treated with 10ml of chloroform and filtered. The filtrate
was used to test the presence of phytosterols and Triterpenoids.
 Libermann’s Test
To 2ml filtrate in hot alcohol, few drops of acetic anhydride was added.
Formation of brown precipitate indicates the presence of sterols.
 Libermann’s Burchard Test
100mg of extract was treated with 2ml of chloroform and filtered. To the filtrate
few drops of acetic anhydride was added, boiled and cooled. Conc H2So4 was added
through the sides of the test tube. Formation of brown ring at the junction indicates the
presence of steroidal saponins.
 Salkowaski Test
To the test extract solution few drops of Conc H2So4 was added, shaken and
allowed to stand, lower layer turns red indicates the presence of sterols. (Peach and
Tracey)
5.4.3 Detection of Flavoniods
 Shinoda Test
To 100mg of extract, few fragments of magnesium metal were added in a test
tube, followed by dropwise addition of Conc Hcl. Formation of magenta colour
indicates the presence of flavonoids.
 Alkaline Reagent Test
To 100mg of extract, few drops of sodium hydroxide solution was added in a
test tube. Formation of intense yellow color that becomes colorless on addition of few
drops of dilute acid (Hcl) indicates the presence of flavanoids. (Shellard, 1957)
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5.4.4 Detection of Saponins
 Foam test
The extract was diluted with 20ml of distilled water and it was shaken in a
graduated cylinder for 15 minutes. A 1cm layer of foam indicates the presence of
Saponins.
5.4.5 Detection of Proteins and Amino acids
100mg of extract was taken in 10ml of water and filtered. The filtrate was used to
test the presence of protein and amino acids.
 Millon’s Test
2ml of filtrate was treated with 2ml of millon’s reagent in a test tube and heated in
a water bath for 5 minutes, cooled and few drops of NaNo2 was added. Formation of
white precipitate, which turns to red upon heating, indicates the presence of proteins and
amino acids.
 Ninhydrin Test
2ml of filtrate, 0.25% ninhydrin reagent was added in a test tube and boiled for 2
minutes. Formation of blue color indicates the presence of amino acids.
 Biuret Test
2ml of filtrate was treated with 2ml of 10% sodium hydroxide in a test and
heated for 10 minutes. A drop of 7% copper sulphate solution was added in the above
mixture. Formation of purplish violet indicates the presence of Proteins. (Finar, 1959)
(Hawk, 1954)
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5.4.6 Detection of Fixed oils and Fats
 Oil spot test:
One drop of extract was placed on filter paper and the solvent was evaporated.
An oily stain of filter paper indicates the presence of fixed oil. (Rosenthalar, 1930)
5.4.7 Detection of Phenolics and Tannins
100mg of extract was boiled with 1ml of distilled water and filtered. The filtrate
was used of the test.
 Ferric chloride Test
To 2ml of filtrate, 2ml of 1% ferric chloride was added in a test tube. Formation
of bluish black color indicates the presence of Phenolic nucleus.
 Lead acetate Test
To 2ml of filtrate, few drops of lead acetate solution was added in a test tube.
Formation of yellow precipitate indicates the presence of Tannins.
5.4.8 Detection of Carbohydrate
500mg of extract was dissolved in 5ml of distilled water and filtered. The filtrate
was used to test the presence of carbohydrates.
 Molisch’s test
To one ml of filtrate, two drops of Molisch’s reagent was added in a test tube
and 2ml of Conc H2So4 was added carefully along the side of the test tube. Formation of
violet ring at the junction indicates the presence of carbohydrates.
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 Fehling’s test
To one ml of filtrate, 4ml of Fehling’s reagent was added in a test tube and
heated for 10 minutes in a water bath. Formation of red precipitate indicates the
presence of reducing sugar.
 Benedicts Test
Filtrate was treated with Benedict’s reagent and heated on water bath. Formation
of orange red precipitate indicates the presence of reducing sugars. (Rosenthalar, 1930)
5.4.9 Detection of Glycosides
0.5gm of extract was hydrolyzed with 20ml of dilute Hcl (0.1N) and filtered. The
filtrate was used to test the presence of glycosides.
 Modified Borntrager’s test
1ml of filtrate 2ml of 1% ferric chloride solution was added in a test tube and
heated for 10 minutes in boiling water bath. The mixture was cooled and shaken with
equal volume of benzene. The benzene layer was separated and treated with half its
volume of ammonia solution. Formation of rose pink or cherry color in the ammonical
layer indicates the presence of anthranol glycoside.
 Legal’s test
To 1ml of filtrate, 3ml of sodium nitropruside in pyridine and methanolic alkali
(KoH) was added in a test tube. Formation of pink to blood red color indicates the
presence of cardiac glycoside.
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 Keller Killiani Test
Small portion from the extract was shaken with 1ml of Glacial acetic acid
containing trace of ferric chloride. 1ml of Conc H2So4 was added carefully by the sides
of the test tube. A blue color in the acetic acid layer and red color at the junction of two
liquids indicate the presence of glycosides. (Hawk, 1954)
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4.5 ACUTE ORAL TOXICITY STUDY OF METHANOL EXTRACT OF
Pergularia Daemia. LEAVES
Animals
Swiss albino mice of female sex weighing 20-25gms were used for the study.
The animals were obtained from Agricultural University, Mannuthy, Thrissur, kerala
(328/99/CPCSEA) and were housed in polypropylene cages. The animals were
maintained under standard laboratory conditions (250 + 20C; 12hr light and dark cycle).
The animals were fed with standard diet and water ad-libitum. Ethical clearance (for
handling of animals and the procedures used in study) was obtained from the
Institutional Animal Ethical Committee (IAEC) before performing the study on animals.
Acute oral toxicity study for methanol extract of Pergularia daemia. a leaf was
carried out as per OECD guidelines 425 (Up and Down procedure). The test procedure
minimizes the number of animals required to estimate the acute oral toxicity. The test
allows the observation of signs of toxicity and can also be used to identify chemicals
that are likely to have low toxicity. Animals were fasted (food but not water was with
held overnight) prior to dosing. The fasted body weight of each animal was determined
and the dose was calculated according to the body weight.
 Limit test at 2000mg/kg
The drug was administered in the dose of 2000mg/kg body weight orally to one
animal. If the test animal survived. Then four other animals were dosed sequentially;
therefore, a total of five animals were tested. Animals were observed individually at
least once during the first 30 minutes after dosing, periodically during the first 24 hours
(with special attention given during the first 4 hour), and daily thereafter, for a total of
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14 days. After the experimental period, the animals were weighed and humanely killed
and their vital organs including heart, lungs, liver, kidneys, spleen, adrenals, sex organs
and brain were grossly examined. (OECD Guidance; 2000)
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Evaluation of hypolipidemic activity of methanol extract of Pergularia daemia
leaves.
Healthy Albino rats (Wistar strain) of either sex weighing 150-200g were used
for the study. The animals were obtained from Agricultural University, Manuthy,
Thrissur, Kerala.
The animals were housed in polypropylene cages and were maintained under
standard laboratory conditions (25 0 ± 20c, 12 hr light and dark cycle). The animals were
fed with standard pellet diet and water ad libitum.
Ethical clearance (for handling of animals and the procedures used in study) was
obtained from Institutional Animal Ethical Committee (IAEC) before performing the
study on animals. (20MP01DEC10)
Cholesterol Diet:
Rats were made hyperlipidemic by the oral administration of high cholesterol diet
(regular diet mixed with 2% w/w cholesterol, 1% w/w sodium cholate, 2.5% w/w
coconut oil) to healthy rats for 30 days. (Pandya et al., 2006), (Rumi Ghosh et al.,
2010).
Experimental Design:
The rats with elevated cholesterol level were divided into 3 groups of 6 animals each
and given drug/ vehicle treatment for 15 days. A group of 6 normal animals were
included in the study.
Group I animals served as normal control fed with normal diet.
Group II animals served as a Hypercholesterolemic Control (HC- C).
Animals received vehicle (CMC 0.5%) 2 ml/kg P.O.
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Group III Hypercholesterolemic animals received methanol extract of
Pergularia daemia 200 mg/kg P.O once daily orally for 15 days.
Group IV Hypercholesterolemic animals received methanol extract of
Pergularia daemia 400 mg/kg P.O once daily orally for 15 days.
At the end of experimental period, the animals were fasted overnight and fasting
blood samples were collected by retro orbital vein puncture technique in clot activator
tube. The samples were centrifuged at 4000-5000rpm to separate serum, which was
subjected for the estimation of lipid profile.
Estimation of lipid profiles
The total cholesterol in plasma was estimated by cholesterol oxidase enzymatic
method using Agappe Diagnostic kit (Siedel et al., 1981). Plasma triglyceride (TGL)
was estimated by Autoanalyser using enzymatic-GPO method (Rifai et al., 1999). High
density lipoprotein (HDL) was estimated by selective precipitation followed by
cholesterol oxidase enzymatic method using HDL-cholesterol phosphotungstic acid of
Erba diagnostic Mannheim gmbh kit (Burstein et al., 1970). Low density lipoprotein
(LDL) was estimated by direct measurement with the homogeneous method performed
with the reagent LDL-C Select FS (DiaSys) (Caio Mauricio Mendes de Cordova et
al., 2004). Very low density lipoprotein (VLDL) was calculated using the formula
TGL/5 (Vijayabaskar et al., 2008). Atherogenic Index (AI), which is a measure of the
atherogenic potential of an agent, was calculated using the following formula and the
results were tabulated (Rekha and Ekambaram, 2010).
Atherogenic Index (AI), which is a measure of atherogenic potential, was
calculated using the following formula
Total serum HDL
Atherogenic Index = --------------------------------
Total serum cholesterol
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AI of control – AI of treated group
Percentage protection = -------------------------------------------------- X  100
AI of control
ESTIMATION OF BIOCHEMICAL PARAMETERS
Total Cholesterol, HDL, LDL, VLDL, triglycerides and phospholipids were
estimated in serum. All the biochemical parameters were estimated using semi-
autoanalyser (photometer, Germany) with enzymatic kits.
Estimation of Serum Total cholesterol (TC)
Principle
Determination of cholesterol was done after enzymatic hydrolysis and oxidation.
The colorimetric indicator is quinoneimine, which is generated from 4-aminoantipyrine
and phenol by hydrogen peroxidase under the catalytic action of peroxidase (Trinder’s
reaction).
Cholesterol ester + H2 CHO Cholesterol + Fatty acid
Cholesterol + O2 CHO Cholesterol-3-one + H2O2
2H2O2 + Amino antipyrine + phenol POD Quinoneimine + H2O2
Method
CHOD-PAP: enzymatic photometric test
Table 3 Reagents
1 goods buffer( pH
6.7)
50mmol/I
2 Phenol 5mmol/I
3 4-amino antipyrine 0.3mmol/I
4 Cholesterol
esterase
>200 U/I
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Assay procedure
a. 1ml (1000 µl) of reagent-1 has taken in a 5ml test tube.
b. Added 0.01 ml (10 µl) of serum.
c. Mixed well and incubated at 370C for 5 min.
d. The sample was tested by using photometer.
NORMAL RANGE: <200 mg/dl in serum.
Estimation of Serum Triglycerides (TG)
Principle: Determination of triglycerides (TG) alters enzymatic splitting with
lipioprotein lipase. Indicator is quinoneimine which is generated from aminoantipyrine
and 4-chlorophenol by hydrogen peroxidase under the catalytic action of peroxidase.
Triglycerides LPL Glycerol + fatty acid
Glycerol + ATP GK Glycerol-3-phosphate + ADP
Glycerol-3-phosphate + O2 GPO Dihydroxy acetone phosphate + H2O2
2H2O2+4-amino antipyrine+4-chlorophenol POD Quinonelimine+HCL+4 H2O2
Method
Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO).
5 Cholesterol oxidase >100U/I
6 Peroxidase 3 KU/I
7 Standard 5.2
mmol/I
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Reagents
Components and concentrations in the test goods buffer pH 7.2, 50 mmol/I
Table. 4 Reagents
4 chloroPhenol 4mmol/l
ATP 2mmol/l
Mg2+ 15mmol/l
Glycerokinase >0.4 Kµ/l
Peroxidise >2 Kµ/l
Lipoprotein lipase >4 Kµ/l
4-aminoantipyrine 0.5 mmol/l
Glycerol-3-phosphate-
oxidase
>1.5 Kµl/l
Standard (2.3
mmol/l)
Assay procedure
a. 1 ml (1000ml) of reagent-1 has taken in a 5 ml test tube.
b. Added 0.01 ml (10µl) of serum.
c. Mixed well and incubated at 370C for 15min.
d. The sample was tested by using photometer.
NORMAL RANGE: <200 mg/dl in serum.
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Estimation of serum HDL
Principle
Chylomicrons, VLDL, and LDL are precipitated by adding phosphotungstic acid
and magnesium ions to the sample. Centrifugation leaves only the HDL in the
supernant. The cholesterol content in it is determined enzymatically.
Method
Phosphotungstic acid precipitation method.
Table. 5 Reagents
Phosphotungstic
acid
0.55
mmol/l
Magnesium
chloride
25 mmol/l
Assay procedure
Preparation of supernatant for the HDL estimation
A. Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent (from
HDL kit) in 1.5 ml centrifuge tube and mixed well and centrifuged the above solution at
4000rpm for 10 min.
B. Preparation of test sample for the estimation of HDL-cholesterol
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5ml test tube.
b. Added, 100 µl of supernatant from above centrifuged solution.
c. The sample was tested by using photometer.
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Estimation of serum low-density lipoprotein cholesterol (LDL)
Using the data obtained including total cholesterol, HDL cholesterol and VLDL,
the LDL cholesterol levels were calculated using the empirical equation of Friede Wald
Calculation:
Serum LDL cholesterol = Total cholesterol -(HDL cholesterol+ VLDL
cholesterol)
Estimation of serum very low-density lipoprotein cholesterol (VLDL)
Using the data obtained including triglycerides, the VLDL cholesterol levels
were calculated using empirical equation of Friede Wald calculation:
Serum cholesterol VLDL= Triglycerides/5
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HISTOPATHOLOGICAL TECHINIQUES
Immediately after collection of blood the animals were sacrificed by cervical
decapitation. The liver was separated, washed with pH 7.4 buffer, blotted with dry filter
paper and the organ weight was recorded.
Histopathology
A small portion of the liver tissues from all the groups was excised immediately after
sacrifice and fixed in 10% neutral formalin. The washed tissues were dehydrated in
descending grades of isopropanol and cleared in xylene. The tissues were then
embedded in molten paraffin wax. Sections were cut at 5 μm thickness and stained with
hematoxylin and eosin and then viewed under light microscope for histopathological
changes.
Statistical analysis
Results are expressed as mean ± SEM (standard error of mean). Results were
analysed statistically by one-way ANOVA followed by Dunnett’s test using Prism
(Graphpad Software Inc., La Jolla, CA Trial version). The criterion for statistical
significance was set at p < 0.05.
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Phytoconstituents detected in methanol extract of Pergularia daemia leaves
Table. 6
S. No. Test Inference
1.
Test for Alkaloids
a.  Mayers test
b.  Wagner’s test
c.  Dragen draft’s test
+
+
+
2.
Test for Phytosterols and Triterpenoids
a.  Leibermann’s test
c.  Salkowaski test
+
+
3.
Test for Flavonoids
a. Alkaline reagent test
b. Lead acetate test
+
+
4.
Test for saponins
Foam test +
5.
Test for Proteins and Aminoacids
a.  Millon’s test
b.  Ninhydrin test
c.  Biuret test
-
-
-
6. Test for fixed oils and fats
Oily spot test +
7.
Test for Phenolics and Tannins
Ferric chloride test +
8.
Test for carbohydrates
a. Molisch’s test
b. Fehling’s test
c. Benedict’s test
+
+
+
9.
Test for Gylcosides
a. Modified Borntrager’s test
b. Legal’s test
c. Keller-Killiani test
+
+
+
(+) Present, (-) Absent.
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Acute oral Toxicity study of methonalic extract of Pergularia daemia leaves.
(Guideline425)
Observations
Table. 7
RESPIRATORY BLOCKAGE IN NOSTRIL
Dyspnoea Nil
Apnoea Nil
Tachypnea Nil
Nostril discharge Nil
MOTOR ACTIVITIES
Locomotion Normal
Somnolence Nil
Loss of righting reflex Nil
Anaesthesia Nil
Catalepsy Nil
Ataxia Nil
Toe walking Nil
Prostration Nil
Fasciculation Nil
Tremor Nil
CONVULSION (INVOLUNTRAY CONTRACTION)
Clonic/tonic/tonic-clonic convulsion Nil
Asphyxial convulsion Nil
Opistotones (titanic spasm) Nil
REFLEXES
Corneal Normal
Eyelid closure Normal
Righting Normal
Light Normal
Auditory and sensory Normal
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OCULAR SIGNS
Lacrimation Nil
Miosis Nil
Mydriasis Nil
Ptosis Nil
Chromodacryorrhea Nil
Iritis Nil
Conjunctivitis Nil
SALIVATION
Saliva secretion Nil
PILOERECTION
Contraction of erectile tissue Nil
ANALGESIA
Decrease in reaction to induced pain Nil
MUSCLE TONE
Hypo or hypertonia Nil
GIT SIGN
Solid  dried / watery stool Nil
Emesis Nil
Red urine Nil
SKIN
Oedema Nil
Erythema Nil
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Table 8: Effect of Pergularia daemia methonalic extract on body weight in high fat diet induced hypercholesterolemic rats
Groups Treatment Initial weight gm(s) Final  weight gm(s) Weight gain % increase in Body
weight
Group I Normal diet 121.7±11.88 130.9 ±1.33 9.23±0.649 7.58 %
Group II Extract 200mg/kg + Normal diet 135.7±12.16nsa 140.8 ±5.509nsa 5.16 ±1.218nsa 3.82 %
Group III Extract 400mg/kg + Normal diet 130.0 ±6.952nsa 138.8 ±7.463nsa 8.862±1.254**a 6.81 %
Group IV High fat diet(HFD) 165.0 ±5.77nsb 195.8 ±5.449nsb 30.81 ±1.217***b 18.67 %
Group V Extract 200mg/kg +HFD 158.3 ±6.67nsc 167.5 ±8.827nsc 9.216±0.654***c 5.81 %
Group VI Extract 400mg/kg +HFD 144.2 ±8.7nsc 148.5 ±5.881nsc 4.350±0.427***c 3.01 %
All the values are expressed as mean ± SEM, n = 6 in each group.
aValues are significantly different from  group I. Non significant (ns); *p < 0.05; **p < 0.01; ***p < 0.001
bValues are significantly different from group I. Non significant (ns); *p < 0.05; **p < 0.01; ***p < 0.001
CValues are significantly different from group IV. Non significant (ns); *p < 0.05; **p < 0.01; ***p < 0.001
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Figure No 5.
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON BODY WEIGHT GAIN
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Table 9: Effect of methonalic extract of Pergularia daemia leaves on serum lipid profiles in rats fed with high fat diet
Group Treatment Total cholesterol
mg / dl HDL mg / dl LDL mg / dl
Triglyceride
mg / dl VLDL mg / dl
Group I Normal diet 175.0±8.851 27.83 ±8.851 73.17 ±5.294 110.0 ±10.25 19.33±1.476
Group II High fat diet (HFD) 212.5 ±8.839**b 13.33±0.988***b 100.8 ±5.23**b 167.5 ±14.82***b 23.33±2.246nsb
Group III Normal diet +
200mg/kg
150.0 ± 7.303nsa 16.17±1.424**a 70.50 ±3.97nsa 108.7 ±3.180nsa 18.0±0.9309nsa
Group IV Normal diet + 400
mg/kg Extract
139.2 ±6.509**a 22.50±2.895nsa 65.83 ±4.16nsa 95.83 ± 4.16nsa 16.33±1.382nsa
Group V Extract 200mg/kg +
HFD
150.8 ±7.12***c 20.17±2.786nsc 74.0 ±6.583**c 102.5 ±4.425***c 17.5±1.607*c
Group VI Extract 400 mg/kg
+ HFD
117.8 ±5.002***c 27.17 ±1.641***c 67.83±4.324***c 97.50 ± 3.81***c 15.17±0.833**c
All the values are expressed as mean ± SEM, n = 6 in each group.
aValues are significantly different from  group I. ns; *p < 0.05; **p < 0.01; ***p < 0.001
bValues are significantly different from group I. ns; *p < 0.05; **p < 0.01; ***p < 0.001
cValues are significantly different from group IV. ns; *p < 0.05; **p < 0.01; ***p < 0.001
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Figure No. 6
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON SERUM CHOLESTEROL
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Figure No. 7
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
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Figure No. 8
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON SERUM LDL
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Figure No. 9
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON SERUM TRIGLYCERIDES
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Figure No. 10
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON SERUM VLDL
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Table 10: Atherogenic index of Pergularia daemia methonalic extract
Group Treatment Atherogenic index Percentage (%)
Protection
Group I Normal diet 3.95 ±0.328 --
Group II High fat diet (HFD) 12.56 ± 0.921***b --
Group III Extract (200 mg/kg) +Normaldiet 6.722 ± 0.527
nsa 33.56%
Group IV Extract  (400 mg/kg)+ Normaldiet 4.25 ± 0.358
nsa 55.23%
Group V Extract  (200 mg/kg)+HFD 5.08 ± 0.625***c 52.70%
Group VI Extract  (400 mg/kg)+HFD 3.58 ± 0.268***c 70.62%
All the values are expressed as mean ± SEM, n = 6 in each group.
aValues are significantly different from  group I. ns;*p<0.05;**p < 0.01;***p<0.001
bValues are significantly different from group I. ns;*p <0.05;**p<0.01;***p< 0.001
cValues are significantly different from group IV. ns;*p <0.05;**p<0.01;***p< 0.001
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Figure No. 11
EFFECT OF PERGULARIA DAEMIA LEAVES EXTRACT
ON ATHEROGENIC INDEX
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Histopathological examination Of Liver
Figure No. 12
(a) Section of liver of control group rat on normal diet. (H&E 10x)
Normal liver with intact lobular architecture, normal central veins and sinusoids
(b) Normal portal tracts without inflammation
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Figure No. 13
(a) Section of liver of rat fed with high fat diet showing large dilated space with
fibrous wall and amorphous material. (H&E 10x)
(b) Section of liver of rat fed with high fat diet showing normal portal tracts and
lobular inflammation.(40X)
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Figure No. 14
(a) Section of liver of rat given methonal extract of Pergularia daemia 200mg/kg
along with high fat diet showing fibrous wall with inflammation and
macrophages (H&E 10x)
(b) Section of liver of rat given methonal extract of Pergularia daemia 200mg/kg
along with high fat diet showing dilated central vein (H&E 10x)
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Figure No. 15
(a) Section of liver of rat given methonal extract of Pergularia daemia
400mg/kg along with high fat diet showing lobular inflammation (H&E
40x)
(b) Section of liver of rat given methonal extract of Pergularia daemia
400mg/kg along with high fat diet showing portal tract with mild
inflammation (H&E 40x)
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Figure No. 16
(a) Section of liver of rat given methonal extract of Pergularia daemia
200mg/kg along with normal diet showing normal sinusoids and central
vein (H&E 40x)
Figure No. 17
(a) Section of liver of rat given methonal extract of Pergularia daemia
400mg/kg along with normal diet showing dilated central vein (H&E
40x)
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Preliminary phytochemical study of Pergularia daemia extract showed the
presence of phytosterols, triterpenoids, flavonoids, carbohydrates, glycosides, phenolic
compounds, tannins, and fixed oils, fats. The results are shown in Table 6.
The effect of Pergularia daemia extract on body weight of rats with high fat
diet is shown in Table 8. A significant increase (P<0.001) of weight gain (30.812
±1.217) was found in rats fed with cholesterol diet compared to rats fed with normal
diet (9.23±0.649). Administration of Pergularia daemia extract once daily orally for
15 days for rats fed with high fat diet significantly prevented the body weight gain. A
dose level of 400mg/kg Pergularia daemia extract was found to be highly significant
(P<0.001) when compared to cholesterol fed animals. The animals treated with
400mg/kg Pergularia daemia extract showed increase in average weight gain of 4.350
gms from the initial weight.
The effect of Pergularia daemia extract on lipid profile in control and rats fed
with high fat diet is shown in Table 9. Total cholesterol levels were significantly
increased (P<0.001), (212.5 ±8.839) in high fat diet fed rats compared to animals fed
with normal diet (175.0±8.851). Administration of Pergularia daemia extract 200
mg/kg once daily orally for 15 days show significant change (150.8 ±7.120) in
cholesterol level compared to rats fed with high fat diet. The results were non-
significant (ns). The animals treated with 200 mg/kg and 400 mg/kg Pergularia
daemia extract once daily for 15 days are also showed a significant decrease
(P<0.001), (150.8 ±7.120 and 117.8 ±5.002) in cholesterol level compared to rats fed
high fat diet.
The animals on high fat diet showed a significant fall (P<0.001) (13.33±0.988)
in HDL level compared to animals fed with normal diet (27.83 ±8.851). Administration
of Pergularia daemia extract once daily orally for 15 days showed increase in HDL
level in high fat diet fed animals. Both the dose levels (200 mg/kg and 400 mg/kg),
(20.17±2.7860 and 27.17 ±1.641) were showed dose dependent effect.
The animals fed with high fat diet showed a significant increase (P<0.01) in LDL
level (100.8 ±5.23) compared to animals on normal diet (73.17 ±5.294). Administration
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of Pergularia daemia extract once daily for 15 days showed a significant decrease
(P<0.001) in LDL level (74.0 ±6.583 and 67.83±4.324) compared to animals fed with
high fat diet. Both the dose levels (200 mg/kg and 400 mg/kg) were found to be
effective in lowering the LDL level. The results showed the Pergularia daemia extract
is highly effective in reducing the LDL cholesterol level.
The triglyceride levels in animals fed with fat diet were significantly increase
(P<0.001) in triglyceride levels (167.5 ±14.82) compared to animals fed with normal
diet (110.0 ±10.25). Administration of Pergularia daemia extract showed a significant
decrease (P<0.001) in triglyceride level compared to animals fed with high fat diet. A
dose dependent decrease in triglyceride level was noted in Pergularia daemia extract
treated animals. Both the dose levels (200 mg/kg and 400 mg/kg), (102.5 ±4.425 and
97.50 ± 3.81) were found to be effective in reducing the triglyceride levels.
A significant increase in VLDL (23.33±2.246) level was noted in rats fed with
high fat diet compared to rats fed with normal diet (19.33±1.476). Administration of
Pergularia daemia extract 400 mg/kg daily for 15 days showed significant (P<0.01),
(15.17±0.8330) decrease in VLDL compared to animals fed with high fat, but the results
of VLDL in animals treated with 200 mg/kg Pergularia daemia extract was less
significant(P<0.05).  The results showed the Pergularia daemia extract at a dose level
of 200 mg/kg and 400mg/kg was effective in lowering VLDL level.
A significant increase in HDL-cholesterol which was related to a significant
reduction of atherogenic index was observed (Table 10). The atherogenic index was
significantly reduced (P<0.001) in Pergularia daemia extract treated group to high fat
diet fed group. The percentage protection against the hyperlipidemia was found to be
52.70 % with 200 mg/kg Pergularia daemia extract and 70.62 % with 400 mg/kg
Pergularia daemia extract.
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Histopathological examination
Liver
Histopathological examination of liver of control group rat on normal diet
showed normal structure and architecture. There is no evidence of changes in
degeneration, no lobular inflammation, granuloma or fibrosis, Fatty change or
congestion in liver section. The hepatocytes are unremarkable. The central vein and the
sinusoids are normal.
Section of liver of rat fed with high fat diet showed largely dilated duct with
fibrotic wall that show inflammation. There is amorphous material in the lumen of
dilated duct seen. The central veins and sinusoids mildly dilated.  There is no lobular
inflammation, granuloma or fibrosis. The central vein and sinusoids are dilated.
Inflammatory with fatty changes were noted.
Section of liver of rat given Pergularia daemia extract 200 mg/kg along with
high fat diet showed largely dilated duct with fibrotic wall that show inflammation.
There is amorphous material in the lumen of dilated duct seen. The central veins and
sinusoids are mildly dilated. Inflammatory and fatty changes were observed. Pergularia
daemia extract 200 mg/kg showed only a mild restoration of disrobed structure.
Section of liver of rat received 400 mg/ kg Pergularia daemia extract along with
high fat diet showed a marked decrease in inflammatory and fatty changes. The central
vein and sinusoids are mildly dilated. The portal tracts show mild inflammation. The
liver section showed normal lobular architecture and architecture compared to the
section of liver of rats on normal diet. The section showed inflammatory and fatty
changes. The section showed loss of distinct liver characteristic configuration.
Section of liver treated with Pergularia daemia extract 200 mg/kg along with
normal diet showed normal lobular architecture. There is no lobular inflammation,
granuloma or fibrosis. The portal tracts, hepatic parenchyma, the central veins and
sinusoids are mildly dilated.
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Section of liver treated with Pergularia daemia extract 400 mg/kg along with
normal diet showed normal lobular architecture. There is no lobular inflammation,
granuloma or fibrosis. The portal tracts are normal. The hepatic parenchyma is
unremarkable. The central veins are mildly dilated.
From the results, it was observed that Pergularia daemia extract 400 mg/kg was
highly effective in protection the liver function in hyperlipidemic animals.
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DISCUSSION
Hyperlipidemia is a well-known risk factor for cardiovascular diseases, especially to
cause atherosclerotic coronary artery disease (CAD). Plaque formation, thrombosis, and
vessel occlusion can follow, leading to CAD. CAD involves one or more specific
cardiovascular pathologies, including myocardial infarction, ischemia, and angina. Between
13 and 14 million people in the United States are believed to suffer from this complex and
life-threatening condition, and over 25 million people worldwide are expected to die from
cardiovascular-related pathologies by the year 2020.It has been established that nutrition
plays an important role in the etiology of hyperlipidemia and atherosclerosis.
Cholesterol feeding has often used to evaluate serum or tissue cholesterol levels to
assess hypercholesterolemia related metabolic disturbances in different animal models. Rats
were fed with diet supplemented with cholesterol, 1% w/w sodium cholate and 2.5% w/w
coconut oil served as a experimental model to screen anti hyperlipidemic activity. According
to these previous findings reports (Rumi ghosh, et al., 2010) showed that feeding rats with
high cholesterol diet for 7 days was induced hyperlipidemia. Similar results have been
reported feeding rats with a high cholesterol diet for 7 consecutive days resulted in marked
hyperlipidemia. The mechanism of sodium cholate is twofold an increase of cholesterol
absorption and a concomitant suppression of cholesterol 7 α-hydroxylase activity that results
in decreased cholesterol excretion. Sodium cholate (Na+ salt or cholic acid) improves
cholesterol absorption by its emulsifying property. Supplementation of cholesterol in diet
results in a marked increase in the production of cholestryl ester rich-VLDL by the liver and
intestine and a number as well as rate of cholesterol by the hepatic LDL receptors.
Consequently serum levels of LDL-cholesterol and VLDL-cholesterol is increased. Increase
in LDL cholesterol has been pointed out as one of the risk factors for the development of
atherosclerosis and related cardiovascular diseases.
From the obtained results it was observed that the animal on high fat diet significantly
increased the total cholesterol, triglyceride, LDL-cholesterol and VLDL in serum compared
to rats on normal diet. The HDL level was significantly reduced. When high fat diet was co-
administrated with Pergularia daemia extract, the elevated levels of total cholesterol,
triglyceride and LDL-C has shown considerable decline suggesting beneficial modulator
influence on cholesterol metabolism and turnover. It was noted that total cholesterol,
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triglyceride, LDL-cholesterol and VLDL lowering activity of methanol extract of Pergularia
daemia 400 mg/kg was more significant compared to 200 mg/kg Pergularia daemia extract.
The notable changes in the HDL levels in serum were not statistically influenced by
Pergularia daemia extract in rats fed with high fat diet. Elevated serum triglyceride is
considered as independent risk factor for cardiovascular disease.
A significant decline in serum triglyceride level observed in Pergularia daemia
extract treated rats supports the cardiovascular protective influence. Increase in LDL
cholesterol has been pointed out as one of the risk factors for the development of
atherosclerosis and related cardiovascular diseases. Pergularia daemia extract lowered the
LDL cholesterol, which can afford a beneficial role in reducing cardiovascular complications.
One of the possible mechanisms of lowering body weight by Pergularia daemia extract is by
decreased adipocytic lipogenesis excreted by phenolic glycosides. Pergularia daemia
contains plenty of different flavonoid glycosides e.g. quercetin-3-glycoside, quercetin-3-
galactoside, kaempferol-3-galactoside, kaempferol-3-glycoside, kaempferol-3-
malonylhexoside,   isorhamnetin-3-glycoside and isorhamnetin-3- malonylhexoside, phenolic
acid derivatives and other compounds. These evidences strongly support that the Pergularia
daemia extract shows hypolipidaemic activity through multiple mechanisms.
Chapter 7 Conclusion
Dept. of Pharmacology 97 JKK Nattraja College of Pharmacy
CONCLUSION
The deleterious effects of high blood cholesterol and beneficial effects of
lowering blood cholesterol in reducing morbidity and mortality from cardiovascular
diseases are well established. Non pharmacological measures like dietary restriction
and exercise may help in lowering blood cholesterol levels. When such therapy fails,
and in patients with abnormally high blood cholesterol levels, drug therapy is
indicated. The available drugs like statins, fibrates and nicotinic acid though very
effective, have a spectrum of adverse effects and are costly.
A growing attention has been recently focused on the improvement of human
health by consumption of herbal plant like Pergularia daemia, which has excellent
historical health benefits due to presence of plenty of phytoconstituents. A myriad of
nutritional benefits has been attributed to these phytochemicals. Since
phytoconstituents are concentrated largely in leaves and considering it as a health
benefits in treating cardiovascular diseases, a study was carried out to evaluate the
effect of Pergularia daemia extract on rats fed with high fat diet.
The results of the study demonstrated that oral administration of Pergularia
daemia extract evokes a beneficial effect on the hyperlipidemia. This finding
supports its use for the treatment and management of cardiovascular diseases. This
implies that Pergularia daemia leaves extract consumption can prevent or be helpful
in reducing the complication of dyslipidemia associated disorders.
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